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ABSTRACT
Pancreatic cancer is an aggressive form of cancer that is very difficult to detect,
treat resulting in a high rate of mortality. Understanding the molecular basis of pancreatic
cancer and identifying new molecular targets for designing therapeutic interventions is
paramount for improving outcomes in this disease. Notch signaling is a vital
developmental signaling pathway that has been implicated to play both oncogenic and
tumor suppressive roles in pancreatic cancer. Previous studies from other groups have
shown that O-linked glycosylation of Notch signaling plays a key role in the regulation of
Notch signaling. Lunatic fringe (Lfng) is one of the glycosyltransferases that modifies the
O-fucosylated Notch receptors. Dysregulation of glycosylation mediated by Lfng has
been previously shown to result in several Notch-related developmental disorders. While
targeting Notch signaling pathway in cancers has been explored as a potential
therapeutic intervention for several cancers, the status of Notch-related glycosylation
has not been explored.
In the first set of studies, we have characterized the expression pattern of Notch
receptors, ligands and Notch-related glycosyltransferases in human pancreatic cancer
cell lines and human pancreatic cancer specimens from our Rapid Autopsy Program.
These studies identified potential molecular targets in the Notch signaling pathway.
Findings of these studies helped identify Lunatic fringe, a Notch–related
glycosyltransferase, to have increased expression in human pancreatic cancer. To
elucidate the role of Lfng in human pancreatic cancer, we utilized multiple genome
editing approaches to engineer three human pancreatic cancer cell lines with complete
lunatic fringe knockout. These cell lines served as model systems to identify the
phenotypic changes in pancreatic cancer cells upon loss of functional Lfng gene.
Furthermore, we performed next-generation sequencing and polar metabolite analysis to
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help elucidate the impact of Lfng on the transcriptional and metabolic profile of human
pancreatic cancer cell lines.
The findings of our study reveal that Lfng impacts the tumorigenicity of pancreatic
cancer possibly through global changes in transcription and metabolic reprogramming of
cancer cells. These findings of this study provide the basis for further detailed
exploration into the role of Notch-related glycosylation in human pancreatic cancer.
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CHAPTER I. INTRODUCTION
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Pancreas and Pancreatic Cancer
The pancreas is an organ with exocrine and endocrine functions. The major
portion of the pancreas consists of acinar cells, which are responsible for the production
of digestive enzymes including trypsin, chymotrypsin, and lipase. Secretions of the
acinar cells are carried to the intestine through a network of ducts. Ducts of the pancreas
are lined by columnar epithelial cells, which are known as the ductal cells. Acinar cells
and ductal cells together comprise the exocrine compartment of the pancreas.
Interspersed in the pancreas are groups of endocrine cells, named the islets of
Langerhans, which are responsible for the production of hormones that regulate blood
glucose levels in the human body. Histology of the pancreas is shown in Figure 1 (Panel
A-B).

Statistics and Progression
Pancreatic cancer is the seventh leading cause of cancer related deaths globally
and third in United States. There are two major subtypes of pancreatic cancer based on
histological and biological characteristics: Pancreatic Ductal Adenocarcinoma (PDAC)
and Neuroendocrine Tumors (PanNET). PDAC is cancer of exocrine pancreas while
PanNET is cancer is the endocrine cells of the pancreas. Approximately 90% of all
cases of pancreatic cancer cases are of the pancreatic cancer cases are of PDAC
subtype. The overall 5-year survival rate of patients diagnosed with PDAC is
approximately 7% (1). According to statistics from the American Cancer Society (2),
PDAC patients diagnosed in late Stage III or Stage IV show 5-year survival of
approximately 3%. A majority of patients with PDAC are diagnosed in advanced stages
when the cancer has spread to distant organs. Advanced stage diagnosis of pancreatic
ductal adenocarcinoma is challenging to treat. Challenges associated with treatment of
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pancreatic cancer patients with end-stage disease include limited chemotherapeutic
options, inoperable nature of cancer due to the involvement of blood vessels, extensive
metastatic burden, chemorefractory nature of the disease, as well as relapse following
surgery (3). Investigation of molecular mechanisms that contribute to the development
and progression of pancreatic cancer could help identify novel molecular targets for
treating pancreatic cancer. PDAC is characterized by an intense desmoplastic reaction.
The histology of PDAC is shown in Figure 1 (Panel C-D).
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Figure 1: Histology of normal pancreas and human pancreatic ductal adenocarcinoma
Representative images of human (A-B) Normal Pancreas and (C-D) Pancreatic Ductal
Adenocarcinoma. The formalin fixed paraffin embedded histological sections were
counterstained using hematoxylin and imaged at 200X using a Nikon Eclipse 90i at 200X
magnification. Histological architecture of normal pancreas is characterized by the
compact arrangement of the endocrine and exocrine cells.
(A-B) White arrowheads show the acinar cells of the pancreas. Black arrowheads point
to the ductal cells of the pancreas. (C-D) Intense stromal reaction and tumor cells
characterize the histological architecture of human pancreatic ductal adenocarcinoma.
The black arrowheads show tumor cells. The white arrowheads indicate the stromal
reaction in the pancreatic cancer tumor microenvironment.
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Figure 1
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Development of Pancreatic Cancer
Cell growth in normal human tissues is highly regulated. Regulatory mechanisms
in normal cells prevent abnormal proliferation and serve to maintain normal tissue
histological architecture. During pancreatic carcinogenesis, some cells of the pancreas
accumulate genetic alterations, leading to progressive stages of transformation. As a
result of these genetic aberrations, normal cells are able to escape regulatory
mechanisms that are in place to prevent the abnormal proliferation and movement
(invasion) by these cells.
There are four major genetic alterations that are known to occur in patients with
pancreatic cancer (4). Ninety percent of all pancreatic cancers have activating mutations
in the Kras oncogene. Fifty to seventy-five percent of PDAC patients have alterations in
tumor suppressor p53 protein. Studies using mouse genetically engineered mouse
models (GEMM) have shown that pancreas specific activating mutations in Kras alone
are insufficient in generating PDAC tumors, however, mutations in Kras and p53
together give rise to spontaneous PDAC (5). Loss of Cyclin dependent kinase Inhibitor
2A (CDKN2A) and SMAD4 are also commonly observed in PDAC (6). As a result of the
accumulation of mutations or epigenetic alterations, normal cells of the pancreas
undergo a transition to pancreatic intraepithelial neoplasia (PanIN). As PanIN lesions
accumulate genetic abnormalities they transition into higher grade PanIN lesions
(PanIN1, PanIN-2, and PanIN-3) eventually transition to give rise to PDAC (7). There is
evidence for accumulation of these genetic aberrations in human pancreatic ductal
adenocarcinoma; however, pancreatic cancer is also characterized by other alteration,
including signaling pathways; changes in post-translational modifications of
biomolecules, and global impact of tumor microenvironment (8–10). As a result of these
altered global genomic and molecular landscape in pancreatic cancer cells, tumor cells
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proliferate uncontrollably and escape checkpoints that otherwise contain the growth of
cells (11).

Mammalian Notch Signaling Pathway
Notch is a highly conserved intercellular signaling pathway that regulates several
important cellular processes, such as cell proliferation, differentiation, development, and
angiogenesis. Notch signaling proteins include Notch receptors and Notch ligands.
Humans express four Notch receptors and five Notch ligands. The four human Notch
receptors are Notch1, Notch2, Notch3, and Notch4. The five Notch ligands are
subdivided into two families: the Delta family, including Delta like ligand-1 (Dll1), Delta
like ligand-3 (Dll3) and Delta like ligand-4 (Dll4); and the Jagged family including
Jagged-1 (Jag-1) and Jagged-2 (Jag-2). Notch receptors and Notch ligands are singlepass transmembrane domain proteins, which are expressed on the cell surface (12).
Notch receptors are comprised of three domains: Notch extracellular domain
(NECD), a transmembrane domain and Notch intracellular domain (NICD). A
representative domain map of a typical Notch receptor is shown in Figure 2. The NECD
makes up the bulk of Notch receptors. Depending on the Notch receptor, the NECD is
comprised of 29-36-epidermal growth factor (EGF) like repeats. Following the EGF like
repeats is a Negative regulatory region (NRR) that includes Lin-12-Notch repeats (LNR)
and a heterodimerization domain. The NRR region prevents the activation of Notch
signaling in the absence of receptor-ligand interaction. The Intracellular domain includes
a RAM domain, seven ankyrin repeats (ANK), a transcription activation domain (TAD)
and a PEST domain (Polypeptide sequences enriched in Proline, Glutamate, Serine,
Threonine, proposed to expedite the degradation of proteins). The RAM and ANK
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domains in the NICD interact with RBPJ, which is an important transcriptional regulator
of Notch signaling (13).
A domain map of Notch ligands is shown in Figure 3. The Notch ligands are also
single pass transmembrane proteins, which have an extracellular domain, a
transmembrane domain, and an intracellular domain. The extracellular domains of
canonical Notch ligands are characterized by an N-terminal domain followed by a
Delta/Serrate/Lag-2 (DSL) domain and multiple EGF-like repeats. The DSL domain and
the first two EGF repeats are necessary for binding to Notch receptor. The N-terminal
(NT) domain includes the N1 region that contains six conserved cysteine residues and
an N2 region that is cysteine free. The intracellular domain of some of the Notch ligands
contains a PSD-95/Dlg/Zo-1 ligand (PDLZ) which has been shown to play a role in cell
signaling independent of Notch receptors. The Jagged ligands contain an additional
cysteine rich domain that is located closer to the cell surface. (14).
Canonical Notch signaling activation requires interaction between the
extracellular domains of Notch receptor and Notch ligands expressed on adjacent cell
membranes. Notch signaling activation is illustrated in Figure 4. Interaction of NECD and
ligand extracellular domains leads to a conformational change in the Notch receptor,
which results in exposure of the cleavage site 2 (S2) on Notch receptors. ADAM (a
disintegrin and metalloprotease enzyme) acts on the S2 site. S2 cleavage acts as a key
regulatory step in Notch signaling activation. Cleavage at the S2 site releases the Notch
extracellular domain resulting in the formation of Notch extracellular domain truncation
(NEXT). NEXT acts as a substrate for gamma secretase complex. The gamma
secretase complex is comprised of nicastrin, presenilin enhancer-2, anterior pharynx
defective-1 and Presenilin enhancer-2 (15–18). Gamma secretase complex cleaves near
the intracellular domain of Notch receptor at site 3 (S3) and releases the NICD from the
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plasma membrane into the cytosol. Following cleavage of the NICD by gamma
secretase, the NICD can translocate into the nucleus. In the nucleus, NICD interacts with
a DNA binding protein RBPJk through the RAM domain. This complex recruits
coactivator Mastermind and thereby regulates transcription of Notch target genes (19).
Notch target genes include Hes-1, Hey-1, among others.
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Figure 2: Domain map of Notch receptors.
Various domains of Notch receptors are depicted. Notch receptors are comprised of an
extracellular domain, transmembrane domain, and intracellular domain. The extracellular
domain has 29-36 EGF (epidermal growth factor)-like repeats. The nuclear localization
signal (NLS) present in the intracellular domain, allows the intracellular domain to
translocate to the nucleus. PEST domain is a site for ubiquitination of NICD that targets
it for proteosomal degradation (20).
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Figure 2
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Figure 3: Domain map of Notch ligands.
Canonical Notch ligands belong to Jagged/Serrate family or Delta family. Both Delta and
Jagged families of ligands have EGF-like repeats in the extracellular domain. The Nterminal DSL region is responsible for interacting with EGF like repeats of Notch
receptors. The Notch ligands have a conserved N-terminal domain (NT) comprised of
the cysteine-rich N1 region and the cysteine-free N2 region. The Jagged/Serrate family
of ligands have an additional cysteine-rich domain located in the extracellular region
(purple). The intracellular domains of Notch ligands have a PDLZ-domain, which
contributes to Notch-independent activity of ligands.
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Figure 3
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Figure 4: Notch Signaling Activation
Notch signaling occurs upon interaction of extracellular domains of Notch receptors and
Notch ligands. The interaction between Notch receptor and Notch exposes cleavage
sites on Notch receptors. Sequential cleavage of Notch receptor (blue arrow- S2
cleavage and red arrow- site for gamma secretase-mediated cleavage) releases Notch
intracellular domain, which translocates into the nucleus and activates transcription of
Notch-target genes. Notch signaling regulates the transcription of genes involved in
important cellular processes.
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Function of Notch Signaling Pathway in Development
Notch signaling is an evolutionarily conserved signaling pathway that regulates
several developmental events and cellular processes. Notch signaling mediates several
diverse processes including lateral Inhibition, border formation, and asymmetric cell fate
designation (21). During normal development, some cells retain the ability to maintain
stem cell characteristics while other cells become differentiated. Cells that maintain their
stem cell like characteristics do so by suppressing this potential in adjacent cell types.
This process is known as lateral inhibition. Notch signaling regulates boundary
formation, cell fate decisions, angiogenesis, and other processes (22).
Asymmetric cell division involves polarization of cell fate determinants into one of
the daughter cells resulting in cell adoption of specialized cell fate by one of the daughter
cell while the other daughter cell maintains stem cell-like phenotype. The earliest
example of asymmetric cell division involving Notch signaling comes from neuronal
differentiation in Drosophila melanogaster in which polarization of Numb proteins in
along one of the mitotic poles results in one of the daughter cells receiving Numb
protein. Numb inhibits activation of Notch signaling pathway and thus forces that
daughter cell to differentiate (23).
Notch signaling has been shown to essential for maintenance of stem cell like
characteristics in various developmental and postnatal contexts. Changes in the degree
of Notch signaling activation in the stem cell population results in differentiation and
commitment to cellular fate. One very good example of this is the differentiation of
intestinal stem cells (ISC) into absorption or secretory cellular fate. Notch signaling
activation is strong in ISC cells and this helps them maintain stem cell characteristics.
ISC cells in which Notch signaling activity is lowered results in commitment to a
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secretory cell lineage. Elevated Notch signaling in ISC cells also helps them to adopt an
absorptive cellular fate (24).

Notch Signaling in Development of Pancreas
Notch plays a vital role in the lateral specification of cells. Numerous reports have
shown that Notch signaling plays an important role in the pancreatic speciation, cell
proliferation, cell fate decisions and plasticity (25–27). Mammalian pancreas develops
from two independent ventral and dorsal buds. Pancreas develops in three stages. In the
primary stage (E9.6-E12.5) there is increased proliferation of pancreatic progenitors.
This stage is also marked by the appearance of glucagon producing cells (28,29). During
the second stage (E13.5-E15.5), all hormone-expressing cells emerge rapidly along with
acinar cells (30,31). During the third stage (E16.5 to E19) endocrine cells migrate in
groups to give rise to islets, and acinar cells proliferate further (32). The most well
characterized role of Notch signaling during pancreas development is the differentiation
of endocrine cells from the progenitor cells via asymmetric cell fate determination. This
model proposes that during the second stage of pancreatic cell differentiation, a
subpopulation of cells express Ngn3. These Ngn3 positive cells eventually give rise to
the endocrine cells of the pancreas. The expression of Ngn3 leads to expression of
Delta ligand in the Ngn3 positive cells. Delta ligand expression in Ngn3 positive cells
activates the Notch receptors expressed on the multiple progenitor cells (MPC) cells,
thus activating Notch signaling pathway in adjacent progenitor cells. Activated Notch
signaling prevents expression of Ngn3 in the MPC cells thereby preventing them from
taking up the endocrine cell fate as the Ngn3 positive cells. Several groups have shown
that alterations of specific Notch signaling proteins impacts the proliferation and
patterning of MPC during different stages of pancreas development.
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While Notch signaling is mostly inactive in the majority of the cells of the adult
pancreas, activity is detected in centroacinar cells and the terminal duct cells (33,34). Indepth studies have shown that Notch signaling pathway is reactivated in the adult
pancreas in several disease conditions and responses, such as pancreatitis (35–38),
PDAC (39,40) and acinar-ductal metaplasia (41,42). In these contexts, Notch signaling
regulates processes such as dedifferentiation and transdifferentiation of the
differentiated pancreatic cells. In vitro studies have also shown that Notch signaling acts
like a gatekeeper of conversion from acinar cells to beta-cells (43–45).

Notch Signaling in Cancer
Studies have shown the involvement of Notch signaling in different types of
cancers including breast cancer, pancreatic cancer, lung cancer, and ovarian cancer.
Interestingly Notch signaling has been shown to have a dual role (tumor suppressive
and oncogenic). Although the mechanisms that contribute to the dual roles of Notch
signaling in cancers still elude us, the effect of Notch signaling activity is highly cell type
and context dependent. Mechanisms that contribute to alterations in Notch signaling
activity include acquiring activating mutations and changes in expression of Notch
signaling proteins. Truncation of all Notch receptors (Notch1- Notch4) both in vitro and in
vivo results in an oncogenic transformation. The expression of various Notch receptors,
Notch ligands and downstream target genes has been found to be dysregulated in
several solid cancer and hematological cancers. Overexpression of Jagged 1 ligand in
Head Neck Squamous cell carcinoma (HNSCC) cells formed larger tumors with
increased vascularization (22).
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Notch Signaling in Pancreatic Cancer
Notch signaling helps maintain progenitor cells in the pancreas and prevents
premature cell differentiation (46). Genetic models have also shown that Hes-1, an
important Notch down-stream effector gene, plays an important role in controlling
exocrine cell plasticity (47). Given the important role of Notch signaling in regulating cell
fate decisions and cell proliferation in normal pancreas, it is not surprising that Notch
signaling is dysregulated in PDAC. Several research groups have manipulated Notch
signaling pathways using genetic approaches as well as chemical approaches to show
the importance of Notch signaling in PDAC.
Steven Leach and colleagues reported the first evidence of the involvement of
Notch signaling in PDAC. Their group characterized the expression of Notch pathway
components in the normal human pancreas, pancreatic cancer precursor lesions, and
pancreatic ductal adenocarcinoma. Their studies showed that Notch receptors (Notch2,
Notch3, Notch4), Notch ligands (Jag1, Dll1) and Notch downstream target genes (Hes1
Hes4, Hey1, HeyL) are overexpressed in PDAC compared to normal pancreas as shown
by qRT-PCR and microarray analysis (48). Further validation using
immunohistochemical analysis also confirmed that Notch signaling components have
increased expression in human pancreatic cancer specimens as compared to normal
pancreas. Their group also showed that Notch signaling components are expressed in
premalignant and invasive lesions generated by transgenic overexpression of
Transforming growth factor (TGF)-alpha in mouse pancreas (48). The activation of Notch
signaling is necessary for TGF-alpha-induced initiation of pancreatic epithelial
metaplasia (48). P. Buchler et al. demonstrated that Notch1 was overexpressed in
nerves; Notch2 and Notch3 are expressed in vascular smooth muscle and Notch4 is
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expressed in the vascular endothelium. Their study also illustrated that Jag1 and NICD
transfection in pancreatic cancer (PC) cell lines resulted in increased expression of
VEGF and cell invasion. Notch signaling was implicated to play a role in neurovascular
development in pancreatic cancer (49).
Mann et al. demonstrated that expression of Notch receptors (Notch1, Notch3,
Notch4) and downstream target genes (Hes-1 and Hey-1) were significantly elevated in
PDAC tumor tissue (resectable and non-resectable) compared to the uninvolved
pancreas. Nuclear expression of Notch3 and Hey1 expression was associated with
reduced overall and disease-free survival following tumor resection (50).
Immunohistochemical analysis has shown that elevated Dll4 expression predicts poor
prognosis after curative PDAC resection (51). Low Dll4 expression in the tumor may
predict benefit from adjuvant gemcitabine therapy after PDAC resection (52).
Kras-induced pancreatic tumor mouse models faithfully recapitulate the process
of PDAC development. To elucidate the role of genes in the Notch signaling pathway in
Kras induced pancreatic tumorigenesis in vivo, several groups have employed gain or
loss of function studies using these mouse models. The simultaneous deletion of both
Notch1 alleles in KrasG12D mice results in increased precancerous lesions (PanIN1B
transitioning to PanIN2) in the pancreas of mice as compared to control KrasG12D Cre
mice (53). Studies using conditional expression in the mouse pancreas showed that
NICD and KrasG12D cooperate to induce PanIN lesions (54). Notch2 is predominantly
expressed in ductal cells and PANIN lesions. Interestingly, deletion of Notch2 halted
PanIN progression, prolonged survival and led to a phenotypic switch to anaplastic
pancreatic cancer in KrasG12D driven pancreatic cancer mouse models. This study also
showed that Notch2 regulates Myc signaling during PDAC tumor development (55). The
contrasting findings from these studies highlight that Notch function and activity is highly
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context dependent. The levels of Notch signaling activation and its cellular context can
contribute to either a tumor suppressive oncogenic role in pancreatic cancer.
Plentz et al. showed that inhibition of gamma secretase slowed tumor
progression in Pdx1-Cre LSL-KrasG12D P53R172H (KPC). This study also tested the
sensitivity of 434 human cell lines derived from various solid tumors to gamma secretase
inhibitors (GSI), which revealed that among the different cancer cell lines in the panel,
pancreatic cancer cell lines were most sensitive to cell proliferation inhibition upon
treatment with GSI inhibitor. They also showed that GSI inhibitors mediated their effect
by blockade of Notch signaling activity (56). Mullendore et al. showed heterogeneous
expression of Notch signaling components in a panel of 20 human PC cell lines. Their
results revealed that expression of Notch ligands Jag2 and Dll4 were elevated in the
majority of human PC cell lines. Genomic sequencing of Notch1 and Notch2 in human
PC cell lines did not reveal any genomic translocation or mutations in the coding region,
which would have allowed ligand independent activation of Notch signaling. These
results implicate that increased Notch signaling activity is mainly due to mechanisms that
increase expression of Notch signaling proteins. Furthermore, genetic and
pharmacological inhibition of Notch signaling revealed a dependence of pancreatic
cancer maintenance on Notch signaling. Treatment of PC cell lines with GSI inhibitor
also decreased ALDH positive tumor initiating cells (57). Cook et al. showed that Notch
inhibition using GSI inhibitor in combination with gemcitabine halted tumor progression in
a genetically engineered mouse model of pancreatic cancer. Their study showed that
GSI mediated inhibition of Notch signaling resulted in decreased intratumoral
vasculature and density in pancreatic cancer. The decrease in intratumoral vasculature
resulted in an increase in tumor cell necrosis (39). Another study showed similar
antitumor effects of GSI when used in combination with gemcitabine using pancreatic
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cancer xenografts (58). In this study inhibition of Notch signaling using GSI not only
reduced tumor growth during active drug administration but also delayed tumor
recurrence after completion of GSI treatment. The antitumor effects of GSI and
Gemcitabine combination therapy in pancreatic xenografts were due to induction of cell
apoptosis, inhibition of cell proliferation and angiogenesis.

Glycosylation in Cancer
Glycosylation is an important posttranslational modification that encompasses
the addition of a wide variety of sugars to proteins and lipids. The glycosylation of
proteins and lipids plays an important role in regulating biological processes such as
embryonic development, immune cell migration and cancer (59–62). Despite our
progress in understanding the cancer genome and gene expression, the impact of the
glycome and glycoproteome are still not understood very well. Proper glycosylation of
proteins has been shown to be vital for maintaining stability, function, and regulation of
protein. Modulation of cell glycosylation of cell surface proteins can regulate fundamental
cellular processes such as cell signaling (63) and communication (64), cell-matrix
interactions (65), angiogenesis (66), cell dissociation and immune modulation (67).
Changes in glycosylation modifications of biomolecules are associated with
several developmental and pathological conditions. Aberrations in glycosylation in
cancer cells that cause altered expression of glycan structures can result from under or
overexpression of glycosyltransferases, dysregulation of chaperone activity or changes
in glycosidase activity, alterations in site/substrate of glycosylation (due to
conformational changes or mutations) or changes in the localization of the
glycosyltransferases and availability of sugar nucleotide donors and cofactors (68).
Increasing evidence suggests a role for glycosylation in tumor formation and metastasis.
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Changes in glycosylation of cell surface proteins can vastly alter protein interaction
domains, thus leading to changes in signaling pathways, invasiveness of tumor cells and
ultimately contributing to changes in the progression of cancer (62). Identifying
alterations in protein glycosylation and investigating its impact on cellular processes of
cancer cells can lead to the development of novel biomarkers and therapeutic targets
(69). Cell signaling events can be mediated by protein glycosylation. A good example of
glycosylation-mediated regulation of signaling transduction is the O-linked glycosylation
of Notch signaling.

O-linked Glycosylation of Notch Signaling Proteins
Given that Notch is an evolutionarily conserved signaling pathway that regulates
the development of and cellular processes in different tissue types, it is clear that Notch
signaling must be regulated and fine-tuned by different mechanisms. Glycosylation of
Notch proteins is one such critical means by which cells regulate Notch signaling.
Nascent Notch receptors receive several glycosylation modifications on their NECD. The
NECD of different Notch receptors include 29-36 EGF like repeats. O-linked
glycosylation of Notch receptors occurs on the hydroxyl side chain of serine/threonine
residues. The EGF repeats of Notch receptors are modified by O-fucose, O-glucose, OGlcNAc, and O-xylose. Each EGF repeat consists of a sequence of 40 amino acids.
These amino acid sequences contain six cysteine residues that form three disulfide
bonds. EGF repeats contain consensus sequences, which dictate the sites for
modification of O-linked glycosylation. C2-X-X-X-S/T-C3 is the consensus sequence for
protein O-fucosyltransferase-1 (Pofut-1). (70) Pofut-1 adds an O-linked fucose to Notch
receptors in the endoplasmic reticulum. (71) Fringe glycosyltransferases extend the Ofucosylated Notch EGF repeat by adding an N-acetylglucosamine. Similarly, O-
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glucosylation of Notch receptors is mediated by Rumi in Drosophila or Protein Oglucosyltransferase 1 (Poglut-1) in mammals.(72). O-glucosylation of Notch mediated by
Rumi is not required for the ligand-binding activity of Notch, however, it has been
suggested that it plays a role in promoting extracellular cleavage of Notch receptor. The
O-glucosylated Notch receptor can be further glycosylated upon by two
xylosyltransferase enzymes (GXYLT)-1 and (GXYLT)-2. (73,74) The xylosylation of
NECD negatively regulates most Notch signaling. Recently, another type of
glycosylation, mucin-type-O-GalNAc, has been shown on NECD (75). The NECD
includes calcium-ion binding domains that play an important role in increasing the rigidity
and stability of EGF repeats (76). The various O-linked glycosylation sites in the single
Notch EGF repeat is illustrated in Figure 5. A previous report has illustrated that Notch
ligands have similar O-linked fucosylation and Fringe modification; however, no Oglycosylation mediated effects on signaling activity have been reported in the literature
(77).

Fringe Glycosyltransferases
The Fringe glycosyltransferase enzymes catalyze the addition of β-1,3 Nacetylglucosamine to the O-fucosylated EGF repeats on the Notch extracellular domain.
Fringe was first discovered in Drosophila where its expression was shown to contribute
to interactions between the dorsal and ventral cells during the wing development (78).
There are three isoforms of Fringe glycosyltransferases: Radical fringe (Rfng), Manic
Fringe (Mfng) and Lunatic Fringe (Lfng) (79,80). Johnston et al. identified three
mammalian isoforms of the Fringe enzyme, Lfng, Mfng and Rfng (80). They also showed
that the Fringe expression demarcates segmental boundaries in the mammalian
embryos and likely act through modulating Notch signaling (80). Later Bork et al.
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suggested that Fringe secreted proteins may function as a secreted glycosyltransferases
(81). Fringe protein was later proposed to modulate specificity of Notch receptor-ligand
interactions by inhibiting Notch-Serrate interactions while potentiating Notch-Delta
interactions (82). Cloning of mammalian fringe genes into mice showed that fringe genes
are expressed in several tissues and the expression boundaries of Fringe genes
coincided with Notch dependent patterning centers and Notch ligand expression
boundaries (79). In mammals, Fringe genes were also found to be involved limb
development (83). While fringe isoform Lfng is expressed in the presomitic mesoderm,
other fringe enzymes were not expressed. Interestingly Lfng deficient mice were found to
have severe defects in somite formation (84). Studies in Drosophila showed that Fringe
acts in the Golgi apparatus and requires the glycosyltransferase signature motif DxD to
be functionally active. This study also showed that Fringe can bind to UDP-nucleoside
which is characteristic of a glycosyltransferase (85). The three mammalian fringe
isoforms recognize similar yet distinct specificity determinants in the O-fucosylated EGF
repeats (86). While these fringe glycosyltransferases recognize similar consensus
sequences, they vary in enzymatic activity for these different substrates (86). Structural
and mechanistic insights into the glycosyltransferase activity of fringe
glycosyltransferase activity were first elucidated through the preliminary analysis of
murine Mfng (87–89). Later, Lfng was shown to co-localize to Golgi complex and to
differentially modulate Jag-1 and Dll1 binding to and signaling through Notch1 and
Notch2 (90). This study showed that Lfng expression potentiates Dll1 binding to Notch1
while inhibiting Jag1 binding to the Notch1 receptor. Interestingly, in the same study Lfng
potentiated both Dll1 and Jag1 signaling via Notch2. These findings suggested that the
modulation of Notch receptor-ligand specificity by Fringe glycosyltransferases could vary
depending on the Notch receptor. As well, an extension of O-fucose β-1,3- Nacetylglucosamine on Notch receptors by other glycosyltransferases may be also be
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required for Fringe mediated regulation of Notch signaling (91).
Recent studies have examined how the three fringe glycosyltransferases
isoforms, Mfng, Rfng and Lfng regulate Notch receptor ligand binding and its impact on
Notch signaling activity (92,93). Studies have shown that each of the fringe
glycosyltransferase isoforms modify a subset of the glycosylation sites present in the
EGF repeats of the Notch receptor extracellular domain. These modifications by fringe
glycosyltransferases result in a distinct pattern on the EGF repeats of the Notch
extracellular domain. The Notch receptor ligand binding and Notch signaling activity is
influenced as a result of this glycosylation patterning. These studies indicate that the
modifications of Notch extracellular domain by Fringe glycosyltransferases enhance the
ligand binding of Delta ligands and Jag1 ligand. Increased Delta ligand binding, as a
result of Fringe mediated modifications, resulted in increased in Notch signaling
activation. Increased Jagged1 binding by this mechanism did not result in increased
Notch signaling activation. These results suggest that the inhibition of Jagged1 mediated
Notch signaling activity is a result of processes subsequent to the initial Notch-Jag1
ligand binding. Fringe-mediated modulation of Notch signaling binding is illustrated in
Figure 6. Understanding how Fringe glycosyltransferase function is a complex task that
needs further investigation.
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Figure 5: O-linked Glycosylation of Notch Receptor
Single EGF-like repeat of Notch receptor is comprised of a 40 amino acid sequence. The
six cysteine residues in the EGF-like repeat form 3 disulfide bonds. O-glycosylation on
the Notch receptors occurs at the serine/threonine residues. The type of O-glycosylation
is regulated by the presence of a consensus sequence in the EGF-like repeats. The
sites for various O-linked glycosylation on a single Notch EGF-like repeat are indicated
in the figure. The glycosyltransferases that catalyze the addition of specific sugars onto
the Notch EGF repeat are mentioned alongside.
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Figure 5

29
Figure 6: Fringe Glycosylation Modulates Notch Receptor-Ligand Interactions
Fringe glycosyltransferase modulates Notch receptor signaling activity by addition of
GlcNAc to O-fucosylated Notch receptor. Modification of Notch receptor by Fringe
glycosyltransferase increases binding to Delta-family of ligands.
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Alterations in Notch Glycosylation in Disease Conditions
Notch is an evolutionarily conserved signaling pathway, which is involved in
several developmental processes. Mutations and dysregulation of Notch signaling
proteins have been implicated in several diseases and developmental defects including
cerebral autosomal dominant arteriopathy with subcortical infarcts and
leukoencephalopathy (CADASIL), Spondylocostal dysostosis (SCOD), Alzheimer
disease and cancer. (94–96)
While alterations in Notch signaling proteins have been characterized in several
diseased conditions, there is also evidence that the glycosylation machinery involved in
the regulation of Notch signaling pathway may also account for pathological conditions
or developmental defects. Principal among this evidence is the original description of the
lunatic fringe in Drosophila, where it was described as having a "notch"-like effect on
Drosophila wing development (78). There is also evidence suggesting that dysregulation
of glycosyltransferases, which regulate Notch signaling contributes to several diseased
conditions. One well-characterized example of dysregulated Notch glycosylation
contributing to the diseased condition is CADASIL. CADASIL is an adult onset hereditary
disorder, which is characterized by transient ischemic attacks, strokes, migraine,
dementia and psychiatric disturbances. (97) Initial studies indicated that the underlying
cause of CADASIL is missense mutations in the Notch3 gene that clustered strongly in
the first 5 EGF repeats of the Notch3 extracellular domain (94,98) However, ArboledaVelasquez and colleagues investigated the effect of CADASIL mutations on the
glycosylation of Notch3 extracellular domain by Pofut-1 and Fringe glycosyltransferase
enzymes. Their study showed that first 5 EGF repeats of Notch3 bearing CADASIL
mutations undergo normal O-fucosylation; however they undergo reduced the extension

32
of O-fucosylated EGF repeats via Lfng glycosyltransferase (95). Studies have also
shown that mutations in Notch ligand Dll3 and Lfng glycosyltransferases give rise to
SCOD. (96,99,100)
Previous studies have shown that Notch signaling plays an important role in
maintaining skeletal muscle homeostasis and skeletal muscle repair following injury
(101). Recent reports have also shown that O-linked glycosylation of Notch receptors
also plays a role in skeletal muscle disorders. Homozygous missense mutations in
Poglut1 causes muscular dystrophy resulting in reduced Notch signaling and loss in
satellite cells (102). The deletion of Pofut1 in skeletal muscles of mice induced agingrelated phenotype in aging-related characterized by decreased satellite cell-self renewal,
increased muscle degeneration, reduced skeletal muscle strength and decreased
myofiber size (103). Thus it is evident that dysregulation of Notch glycosylation results in
several disorders.

Fringe in Cancer
Notch signaling has been implicated as having tumor suppressive or oncogenic
roles in several cancers. Fringe glycosyltransferases are important regulators of Notch
signaling, thus characterizing the expression, and elucidating their role in different
cancers would help understand how Notch signaling is regulated in different cancers. In
CaSki cells (human papillomavirus-related cervical cell line) expression of Manic Fringe
by a recombinant virus resulted in growth inhibition (104). It was also reported that
neoplastic changes observed in the serial passage of isogenic lines of W12 cells (HPV16 positive low-grade squamous intraepithelial neoplasia derived cervical cell line) were
accompanied with an downregulation of Manic Fringe expression (104). Expression of
Mfng is reportedly decreased in lung cancer cell lines and re-expression of manic fringe
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in lung cancer cell lines reduced in vitro and in vivo tumor aggressiveness (105). In
claudin-low breast cancers, expression of Manic fringe is reportedly increased (106).
Mfng expression is shown to enhance in vivo tumorigenicity, cell proliferation and tumorsphere formation (106). Studies have shown that Lfng plays a tumor suppressive role in
prostate cancer (107), while mammary-specific deletion of Lfng induced the formation of
basal-like and claudin-low tumors (108). Lfng has also been shown to aid the metastatic
spread of melanoma (109).

Fringe in Pancreatic Cancer
Svensson et al. characterized the expression of fringe glycosyltransferases in
developing mouse pancreas. Their findings showed that fringe glycosyltransferases
Mfng and Lfng are also expressed in the developing pancreas between embryonic days
9 and 14, while Rfng is not expressed in the developing pancreas. Mfng was colocalized
to with the proendocrine factor Ngn3 while Lfng colocalized with the exocrine marker
Ptf1a. Regulation of dosage and timing of the Notch signaling components is necessary
for proper development of pancreas. Targeted deletion and overexpression of Mfng did
not result in any detectable changes in the development of pancreas, suggesting that
Mfng was dispensable for pancreas development (110).
A recent study showed that Lfng is expressed in a subset of acinar cells (111).
Furthermore, these studies illustrated that pancreas-specific deletion of Lfng in mutant
KrasG12D-Cre (KC) mouse model enhanced pancreatic cancer development in the
presence of mutant Kras (111). The median survival of Lfng knockout KrasG12D Cre
(LKC) mice was significantly shorter than KC mice. Comparison of Notch receptor
expression between the KC and LKC mouse pancreas revealed increased protein
expression of Notch1 and Notch3 receptors while there were no differences in protein
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expression of Notch2, Notch4. Deletion of Lfng in LKC mice resulted in decreased TGFβ signaling thus providing evidence for Lfng mediated regulation of TGF-β (111). These
studies provide evidence for the tumor suppressive role of Lfng in pancreatic cancer and
a crosstalk between Notch and TGF-β signaling. The impact of other Fringe
glycosyltransferases on pancreatic cancer has not been elucidated yet.

Chemotherapeutic Options for Unresectable PDAC
Despite the advances in our understanding of the molecular biology of PDAC,
there have been limited advances in the therapeutic options for treating PDAC. In most
cases of PDAC, the disease is diagnosed during the late stages and hence radiation and
chemotherapy are used as treatment options to halt the progression of the disease.
Current chemotherapeutic drugs used for therapeutic intervention in pancreatic cancer
include Gemcitabine, a combination of 5-fluorouracil, leukovorin, irinotecan, oxaliplatin
(FOLFIRNOX) and a combination of nab-paclitaxel with gemcitabine. The combination
therapies such as FOLFIRNOX, and nab-paclitaxel with gemcitabine have resulted in
modest yet significant overall improvement in survival as compared to gemcitabine
alone; however, the overall median survival from diagnosis is still less than a year (112).
Hence there is a further need to identify new molecular targets for PDAC treatment.
The importance of Notch signaling during the early and advanced stages of
PDAC has been well studied in preclinical settings. Notch signaling has been implicated
to contribute to several oncogenic properties of pancreatic cancer such as aiding cell
proliferation, resistance to chemotherapy, maintenance of cancer stem cell population,
and maintaining tumor vasculature. Given the diverse role of Notch signaling in PDAC,
targeting Notch signaling is an attractive treatment option for PDAC patients. Following
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are several different options that are currently being explored for targeting Notch
signaling.

Targeting Notch Signaling Using Gamma Secretase Inhibitors
Expression of Notch signaling pathway members is often dysregulated in
different cancers. Several groups have implicated the oncogenic role of Notch signaling
in breast cancer, Non-small cell lung cancer (NSCLC), glioblastoma, T-cell acute
lymphoblastic leukemia (T-ALL), and PDAC. Notch continues to be an attractive target
for treating cancer despite the evidence in the literature supporting its oncogenic and
tumor-suppressor roles. Over the last few years, several strategies have been employed
to inhibit Notch signaling. One popular strategy for inhibiting Notch signaling activation,
which has been tested extensively, is the use of gamma secretase inhibitors. All GSI,
despite their diverse chemical structures, prevent the cleavage and release of the Notch
intracellular region from the cell surface by inhibiting the gamma secretase complex,
thus preventing the NICD from translocating to the nucleus.
Inhibition of Notch signaling using GSI in combination with chemotherapy is an
active area of research. Preclinical cancer models have clearly demonstrated that GSI
suppresses the growth of PDAC and other solid tumors. GSIs have been shown to be
capable of capable of blocking the activation of all four Notch receptors, along with
several other proteins, which are processed by gamma secretase. Given the array of
other proteins that can also be affected due to GSI treatment is often associated with
unwanted toxicity in the gastrointestinal (GI) tract (113). GSI administered with
dexamethasone has shown promising results in preclinical animal models to mitigate the
GI tract cytotoxicity associated with the GSI inhibitors (114).
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Anti-Notch Receptor, Anti-Notch Ligand Antibodies and Soluble
Peptides
In an effort to minimize the lack of specificity, toxicity and off-target effects
associated with the GSIs, there is a growing interest to develop Notch receptor and
Notch ligand specific antibodies. These antibodies would allow blocking of specific
members of the Notch signaling proteins and offer an alternative to GSI treatment. A
study using a preclinical mouse model for T-ALL has shown efficacy for inhibition of
Notch1 receptor using Notch1 specific antibody (115). Falk et al. generated Notch1 and
Notch2-specific antibodies to block Notch1 and Notch2 simultaneously. This group
showed that bi-specific blockade of Notch1 and Notch2 in neural stem cells caused them
to differentiate into a neuronal cell fate (116). Thus, specific blockade of Notch receptors
via the use of Notch receptor blocking antibodies has potential to block Notch signaling
in cancer stem cells and thus prevent them from giving rise to tumors.
Notch signaling plays an important role in angiogenesis and maintenance of
normal vasculature (117). Developmental studies have shown that Notch signaling via
Dll4 interactions play an important role in maintaining the normal architecture of blood
vessels (118,119). Blockade of Dll4 results in the formation of non-functional vasculature
which fail to provide oxygen and nutrients sufficient for sustaining tumor growth
(120,121). Anti-Dll4 antibodies for targeting Notch ligand Dll4 has been a popular
molecular target in treating cancer. Another effective method for blocking Notch
signaling is by using soluble forms of Notch receptor extracellular domains or soluble
Notch ligands. Studies using soluble forms of Dll1 can interrupt the Notch receptor ligand
interaction thereby preventing Notch signaling activation and affecting tumor growth
(122).

37

Statement of Research
Based on the literature discussed in the previous sections, it is clear that
regulation of Notch signaling is extremely complex and context dependent. Multiple
Notch receptors and Notch ligands are expressed during pancreas development and
during cancer, however; which ones are important for pancreatic cancer is not clear yet.
The various glycosylation modifications that occur on Notch signaling proteins in PDAC
have not been characterized. Are the changes in Notch signaling activity associated with
changes in O-linked glycosylation in PDAC? How does glycosylation of Notch impact the
ability of NICD to affect gene expression or metabolic reprogramming? We explore these
questions in the work presented in this thesis.
Understanding the contribution of O-linked glycosylation of Notch receptors will
provide useful insights into how it impacts Notch signaling in human pancreatic cancer.
Our work focused on the elucidating the impact of Notch-related glycosyltransferase
Lfng on the oncogenic properties of human pancreatic cancer. Overall, we hypothesized
that aberrant expression of Notch-related O-linked glycosyltransferases contributes to
the progression of pancreatic ductal adenocarcinoma by modulating Notch signaling.
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CHAPTER II. MATERIALS AND METHODS
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Materials and Methods
Cell Lines and Culture Conditions
PANC-1, MIA PaCa-2, CHOK1 and 293T cells were obtained from American
Type Culture Collection. HGC-25 cells were obtained from the originator of the line
(123). HPNE-htert, HPNE-htert Kras, E6/E7 Small t cell lines were a generous gift from
Dr. Michel Ouellette. All cells were cultured in DMEM medium supplemented with 7%
FBS. Cells were maintained at 37°C in a humidified environment with 5% CO2.

Rapid Autopsy Patient (RAP) Samples
Pancreatic tumors were obtained with the consent and IRB approval from
decedents through the Rapid Autopsy Program at the University of Nebraska Medical
Center. To ensure minimal degradation of tissue, organs were harvested within three
hours post-mortem and the specimens flash frozen in liquid nitrogen or placed in
formalin for immediate fixation. The patient samples (primary tumor, liver metastases,
uninvolved tissue controls) were further arranged on to a tissue array for assessment via
immunohistochemistry.

Antibodies and Peptides
Antibodies for Lfng, Notch-1 intracellular domain (Catalog number: bTAN 20)
and Notch-2 (Catalog number: C651.6DbHN) were purchased from Developmental
Studies Hybridoma Bank (DSHB) at University of Iowa. Notch-2 antibody clone D76A6
(#5732) was purchased from Cell Signaling Technology. Notch-3 Clone M-134 (Catalog
number: sc-5593), Notch-4 Clone H-225 (Catalog number: sc-5594), Jagged-1 Clone H114 (Catalog number: sc-8303), Jagged-2 (Catalog number: ab60041), Delta-like ligand4 (ab7280) were obtained from Abcam. Cav1 (sc-894) was obtained from Santa Cruz
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Biotechnology. Hes-1 ab71559, Lunatic Fringe ab102835, Pofut-1 ab74302 Radical
Fringe Peptide ab42428, Lunatic Fringe blocking peptide ab126781. Secondary
antibodies Goat Anti-Rat Ig (Catalog 3010-05) and Goat Anti-Rabbit (Catalog no: 401005) were purchased from Southernbiotech. PE anti-human BioLegend IgG Fc Clone
HP6017, BioLegend PE Mouse IgG2a, k isotype control Clone MOPC-173. Rabbit
polyclonal anti-B-III tubulin (Abcam: ab18207), Rat anti-Lyve-1 (Santacruz Biotechnology
sc65647), Armenian Hamster anti-CD-31 (EMD Millipore: MAB1398Z). Secondary
antibodies used for staining: 488-Donkey anti-rabbit (AlexaFluor A21206), 549-Donkey
anti-rat IgG (DyLight 712-505-150, Jackson ImmunoResearch Laboratories), 649 Goat
anti-Armenian Hamster IgG (DyLight 127-495-160, Jackson ImmunoResearch
Laboratories). Lyophilized human Dll-4 (Fc ligand) 10171-(H02H-50) and human Jag-1
(Fc tag) (11648-H02H-50) was purchased from Sino Biological.

Bacterial Strains and Plasmid Purification
One Shot Top10 chemically competent E.coli (Cat. No C404006) were
purchased from Invitrogen. dam-/dcm- methyltransferase deficient E.coli (Cat. No
C2925I) cells were purchased from New England Biolabs and used for growing
plasmids. The QIAprep Spin Miniprep Kit (Cat. No 27104), QIAGEN Plasmid Maxi Kit
(Cat. No: 12163) and QIAGEN Plasmid Midi Kit (Cat. No:12143) were used for
purification and isolation of plasmids.

Primers and Oligos
The primers used for qPCR are listed in Table 1.The guide sequences and
guide RNAs used to target Lfng catalytic active site are listed in Table 2. The primers
used to assess the cutting efficiency of Lfng targeting guides and the primer for PCR,
RT-PCR based validation for CRISPR-mediated deletions are listed in Table 3. PCR
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primers used to screen the CRISPR- mediated deletion of Lfng are listed in Table 3.
FoxM1 primers used for CHIP are listed in Table 5.

Design and Modification of Multiplex CRISPR/Cas9 Vectors with 2AGFP Tag
Multiplex CRISPR/Cas9 kit was a gift from Takashi Yamamoto (Addgene kit
# 1000000054). The plasmids in this multiplex CRISPR/Cas9 kit allow for cloning in up
to seven targeting guides into the vectors. Thus, this toolkit greatly increases the
efficiency of introducing genetic manipulations at multiple regions of the genome using a
single plasmid. These multiplexing CRISPR/Cas9 plasmids are available in both the
nCas (nickase) and the Cas9 variant thus providing a wide array of options to introduce
genetic manipulations in an efficient manner. While the multiplex CRISPR/Cas9
plasmids provided an all-in-one expression vector for delivery of up to seven guide
sgRNAs along with a Cas9 nuclease/nickase, this vector did not allow the enrichment of
cells to which the multiplex CRISPR/Cas9 plasmid was successfully delivered following
Lipofectamine transient transfection. In order to enrich the CRISPR/Cas9 targeted cell
lines, we modified the multiplex CRISPR/Cas9 nuclease/nickase constructs by cloning
the 2A-GFP DNA sequence from pSpCas9(BB)-2A-GFP (Addgene px458 Plasmid
#48138) construct into the multiplex CRISPR/Cas9 construct.
We used SnapGene software to identify unique feature such as restriction
sites and reporters in the Multiplex CRISPR/Cas9 plasmids and the pSpCas9(BB)-2AGFP. We identified two unique restriction sites, FseI and NotI, that allowed us to
restriction digest the 2A-GFP DNA fragment from px458. FseI and NotI are both
methylation-sensitive restriction enzymes and hence the plasmids were grown in dam/dcm- E.coli bacterial strain prior to restriction digestion. The multiplex CRISPR/Cas9
vectors (px330A 1X2 – px330A 1X7) were all linearized using FseI and NotI. The
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restriction digested 2A-GFP insert and multiplex CRISPR/Cas9 vector backbones were
gel purified and ligated overnight at 16o C using T4 ligase. A 3:1 insert/vector ratio was
used to successfully clone the 2A-GFP into the original multiplex CRISPR vectors with
nuclease/nickase. The successful ligation of 2A-GFP into the Multiplex CRISPR/Cas9
vectors (px330A 1X2 – px330A 1X7) was assessed by restriction digestion using FseI
and NotI restriction enzymes and sequencing.

Design of Plasmid Constructs for Expression of Lfng Wild-Type and
Lfng CRISPR-Edited Variant
gBlock oligos coding for wild-type and CRISPR-edited Lfng lacking the Golgi
localization signal were designed. The sequences of gblocks for wild-type and CRISPR
Cas9 edited Lfng mutant (lacking the catalytic active site) had HindIII and XhoI restriction
flanking the 5’ and 3’ end of the sequence. These restriction sites were utilized to clone
the gblocks for wild-type Lfng and CRISPR-edited Lfng into the psectag2/Hygro
mammalian expression vector (Catalog number V910-20, Thermo Fisher Scientific).
CHOK1 and 293T cells were transfected with the psectag2 vectors coding for
either wild-type or CRISPR-edited Lfng KO cDNA sequence. The cells were selected
using 300µg per ml of hygromycin B (Cat: 400050-100MG, Millipore Sigma). The
supernatant was collected and the his-tagged wild-type and his-Lfng-CRISPR-edited
protein was purified using HisPur Cobalt Resin (Thermo Fisher Scientific: 89965) as per
manufacturers guidelines.

Surveyor Assay
Surveyor Mutation Detection Kit - S100 was purchased from Integrated DNA
technologies. Surveyor nuclease-mediated cleavage relies on detection of single
nucleotide polymorphism. Using this kit, we quantified the cutting efficiency of guide
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RNAs used to target the genes. We prepared the PCR amplicons from CRISPR Cas9
transfected cells and reference DNA. Equal amounts of PCR amplicons from CRISPR
Cas9 transfected cells and reference DNA were mixed and hybridized by heating and
cooling the mixture. The hybridization led to the formation of hetero- and homoduplexed. The annealed hetero and homo-DNA duplexes were then treated with
surveyor Nuclease. As a negative control, the PCR amplicon from reference DNA was
also treated with Surveyor Nuclease. DNA fragments were analyzed using gel
electrophoresis. The reaction conditions for Surveyor Nuclease DNA digestion and the
cleavage intensity by Surveyor Nuclease was measured as per directions previously
described in (124).The Surveyor assay primers used for testing the cutting efficiency of
Lfng targeting CRISPR guides are listed in Table 2

Cloning of Lfng Targeting CRISPR/Cas9 Guides into the Multiplex
Vectors
The two guide RNAs targeting the Lfng exon 7 and the intron following exon
7 were ordered from Eurofins and cloned into the modified multiplex CRISPR/Cas9 2A
GFP vector as previously published (125).

Lentiviral Generation and Generation of Lfng Overexpression Cell
Lines
Stable GFP-tagged Lfng cDNA expressing cell lines were generated by
stable transfection of pLenti-Lfng-mGFP-P2a-Puro using lentiviral transfection. Lentivirus
was generated using HEK 293T cells with the 3:1:4 ratio of psPAX2 and pMD2.G and
Lfng cDNA GFP tag vector or empty control vector. The cells were transfected using
Lipofectamine 3000 from Invitrogen. The lentivirus was collected 24,48 and 72 hours
post-transfection. The virus was passed through a 0.45um SCFA filter and 10µg/ml
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polybrene was added to the filtered media. The parental pancreatic cancer cell lines and
their corresponding cell lines were then transduced using the virus. Cells were selected
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 4 µg/ml Puromycin,
7% FBS. Once cells were selected using puromycin the cells were cultured in DMEM
supplemented with 7% FBS without puromycin.

Immunohistochemical Staining and Immunofluorescence
All immunohistochemistry analyses were performed using Dako EnVision kits.
Antigen retrieval, antibody concentration, and staining conditions were optimized for all
the antibodies using normal tissue specimens. The optimized antibody concentrations,
antigen retrieval conditions, and the control tissue specimen are all listed in Table 4. A
blocking peptide for Lfng antibody was also used for testing the specificity of Lfng
immunohistochemical staining. Formalin-fixed, paraffin-embedded sections of human
PDAC tumor specimens were deparaffinized and rehydrated using the decreasing
gradient of ethanol. Heat-induced antigen retrieval was performed on the sections after
rehydration using conditions listed in Table 4. The endogenous peroxidase activity was
blocked using 3% hydrogen peroxidase solution for 10 minutes. The sections were
incubated in blocking serum supplied in Dako EnVision kit for 30 minutes to minimize
background staining. The sections were incubated with primary antibody and later
washed thrice in 1X PBS. The sections were incubated in horseradish peroxidase
conjugated to a polymer (supplied by Dako Envision Kit), for 30 minutes at room
temperature. Sections were stained using 3,3- diaminobenzidine tetrahydrochloride for
2-4 minutes. The slides were counterstained with hematoxylin and washed in 1X PBS to
rinse off excess stain. The slides were mounted and imaged after staining.
Immunohistochemical staining scored on a scale of 0-4 based on the percentage of
percentage of cells stained positive 0- 0%, 1- 1%-10%, 2- 10%-50% 3- 50%-70% 4-
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70%-100%. The score was converted into a heat map using conditional formatting in
Excel.

RNA Isolation, Quantitative RT-PCR, and RT-PCR
Cells were grown to 80–90% confluence on 15 cm dishes and rinsed with 1X
PBS prior to RNA isolation using the Trizol reagent from Molecular Research Center
(TR118). RNA was aliquoted and stored at −80°C until use. RNA was converted to
cDNA using the Verso cDNA kit (Thermo Scientific AB-1453/B) and cDNA was stored at
−20°C until use. RT-PCR for each primer set was performed in triplicate and SYBR
Green (Applied Biosystems catalog no: 4309155) was used for signal detection. ΔΔCt
method was used to calculate fold change and was converted to relative fold change.
Phusion High-Fidelity DNA Polymerase (Catalog: M0530L) was purchased from New
England Biolabs.

RNA Sequencing
RNA sequencing was performed using RNA isolated from the 3 biological
replicates of PANC-1 and MIA PaCa-2 parental pancreatic cancer cell lines and their
corresponding Lfng KO clones. The RNA was tested for its quality using RNA integrity
analysis and then submitted to UNMC sequencing core for library preparation and
sequencing using Illumina HiSeq2500. Venn diagrams were created using
‘VennDiagram’ package in R. RNA-Seq data for gene expression was analyzed by
mapping RNA-Seq reads to the reference human genome hg19 (GRCh37 genome build)
using Tophat2 (v.2.0.9) and differential expression testing using Cufflinks (v 2.2.1). The
hypergeometric test was performed in R using ‘phyper’ to identify KEGG pathways that
were enriched for the differentially expressed genes. The heat map was created using
‘ggplot2’ package in R.
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Cell Proliferation Assay
Cells were detached from culture plates using trypsin. The trypsin was
neutralized by adding an equal volume of DMEM cell culture media supplemented with
7% FBS. The cells were centrifuged at 3000rpm for 5 minutes and the supernatant was
aspirated. The cell pellet was resuspended in DMEM cell culture media supplemented
with 7% FBS. Cell count of the cell suspension was assessed using a hemocytometer.
Cell proliferation assay was performed by plating cells at a density of 1000 cells/well into
96 well plates. For methylene blue assay, cells were fixed using neutral buffered formalin
at 2, 24, 48, 72, 96 and 120 hours then stained with methylene blue as described in
(126). After each time point, the cells were fixed with 10% buffered formalin and kept in
40C until all the time points were taken. The fixed cells were stained with 1% methylene
blue solution in 0.01M borate buffer (pH 8.5). The plates were rinsed 4 times with 0.01M
borate buffer and the dye was eluted using 100µl 1:1 ethanol and 0.1M HCl. The
absorbance was measured at 650 nm using a plate reader and the results were
normalized to the background.
For Alamar Blue assays, 10% of the final well volume (20µl for 200µl) of
Alamar blue dye was added to each well and incubated at 370C in a humidified incubator
at 5% CO2 for 3 hours. The active component of Alamar blue assay is resazurin, which
is a non-toxic, cell permeable compound. This compound is blue in color and has no
fluorescence. Once resazurin enters the cells it is reduced to resorufin that is a
fluorescent red in color. Live viable cells can catalyze the conversion of resazurin to
resorufin, thus cell viability is indicated by increased fluorescence. Bottom read
fluorescence was measured at excitation wavelength 560nm and emission wavelength
590nm. Alamar Blue Assay was purchased from BioRad (BUF012A) to perform cell
proliferation assay for HGC-25 cells.
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Notch Ligand Binding Assay
Notch ligand binding assay was performed as previously described (127).
Briefly, cells were detached using cell-free Cell Dissociation Buffer (S-004-B, Millipore
Sigma). Ligand binding buffer was prepared as recipe described in (127). 5ml of DMEM
cell culture medium with 7% FBS was added to the cells. The cells were centrifuged at
420 x g using a Sorvall Biofuge Pico centrifuge for 5 minutes. The supernatant was
discarded and the cells were washed with cold ligand binding buffer. Cells were
aliquoted into 1.5ml Eppendorf tubes. The cells were incubated with Dll4-Fc and Jag1-Fc
ligands for 1 hour with rotation at 4 0C. After incubation, cells were centrifuged and the
supernatant was discarded. The cells were washed thrice with ligand binding buffer and
incubated with PE-labeled anti-Fc antibody for 30 minutes with rotation 4 0C. Cells were
centrifuged at

420 x g and the supernatant was discarded. The cells were washed with

ligand binding buffer and then resuspended in ligand binding buffer for flow cytometry
analysis.

Polar Metabolite Extraction and Metabolite Analysis
2 X 106 cells PANC-1, MIA PaCa-2 human pancreatic cancer cell lines and
their corresponding Lfng KO clones were seeded and cultured separately in a 10cm
culture dish. All cells were grown in a DMEM cell culture medium supplemented with 7%
FBS. Cells were incubated at 370C in an incubator containing 5% CO2, and 95%
humidity. Next day, the cell culture medium was replaced with fresh DMEM containing
7% FBS. After 3 days the cell culture medium was detached and the cells were washed
thrice with 1X PBS. The cells were detached using trypsin and the trypsin was
neutralized using DMEM cell culture medium supplemented with 7% FBS. The cells
were centrifuged for 5 minutes at 3000rpm for 5 minutes. The supernatant was
discarded and the cell pellet was resuspended into fresh DMEM cell culture medium
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supplemented with 7% FBS such that the total volume of the cell suspension was
sufficient for five 10cm culture dishes. The cells were then plated into five 10cm culture
dishes to obtain five replicates for each cell line. The cells were allowed to reach 80%
confluence.
24-hours after plating the cells, the cell culture medium was aspirated and the
cells were washed with mass spectrometry grade PBS. The culture dishes were placed
on dry ice to arrest further metabolic activity in cells. 4ml of 80% methanol was added to
each cell culture plates and stored in -800C for 10 minutes. The cells were scraped and
collected in a 15ml polypropylene, conical bottom tube following incubation in -800C. The
tubes were centrifuged at 3000X g for 10 minutes at 40C and the supernatants were
transferred to a new 15 ml centrifuge tube. The samples were evaporated to dryness
using a SpeedVac without heat to remove methanol. The aqueous fractions were frozen
at -800C. The samples were further processed by lyophilization to remove all the water.
The lyophilized samples were reconstituted in100µl of 50% acetonitrile and
vortexed for 15 seconds. The samples were then centrifuged at 16,000 X g for 10
minutes at 40C. 75µl of the sample was then transferred to auto-injector vials for analysis
using LC-MS/MS. LC-MS was performed as per parameters previously described and
data was acquired for each metabolite (128).
The variance for individual metabolites among the different biological replicates
was assessed using statistical variance test. All metabolites with a fold variance > 2
between the biological replicates, and low abundance metabolites were excluded from
the analysis. The data were normalized by using the factor obtained from the ratios of
protein content obtained from Parental (PANC-1 and MIA PaCa-2) control cell lines and
their corresponding Lfng KO clones. Means were obtained for each individual metabolite
for each cell line and their corresponding Lfng KO clones. The peak area for each
metabolite in the Lfng KO cell line replicate was divided by the mean area value for the
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same metabolite in the parental cell line group. These fold change values were used to
plot graphs to represent the relative value of the metabolite.
Normalized data peak area data were arranged as per instructions listed on
MetaboAnalyst website (http://www.metaboanalyst.ca/MetaboAnalyst). Unsupervised
hierarchical clustering analysis, partial least square-discriminant analysis (PLS-DA) and
pathway impact analysis was used as a measure of analyzing the changes in
metabolomics. The pathway impact analysis allows for identification of individual
metabolic pathways altered (such as Pentose Phosphate Pathway, Glycolysis, Purine
Metabolism etc.). PLS-DA analysis allows assessing the clustering pattern between the
replicates of each group. The closer the clustering of the biological replicates in the PLSDA plots the lower the variance among the biological replicates of each sample.

Western Blotting
Proteins lysates were run on 10% Bis-Tris gradient gels (NuPAGE
NP0301BOX, Thermo Fisher Scientific). The proteins were transferred from gels onto
PVDS membrane using Bio-Rad transfer apparatus at 80V for 80 minutes. Membranes
were then washed with 1X PBS and blocked in 5% BSA for 1 hour. Membranes were
incubated with primary antibodies at a concentration of 1ug/ml overnight. Membranes
were washed thrice for 5 minutes each with 0.1% TBST. Membranes were incubated
with secondary antibodies were conjugated to IRDyes (Donkey anti-Rabbit 926-68073,
Donkey anti-Mouse 926-32212) and incubated for 1 hour in dark in 5% BSA.
Membranes were washed three times for 5 minutes each with 0.1% TBST and visualized
using Odyssey Imaging System.
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ChIP Assay
ChIP assays were carried out essentially as described previously (129).
Immunoprecipitation (IP) was performed with antibodies: α-NICD (ab27526), anti-RBPJk
Abcam (ab25949) or control IgG (Santa Cruz) and Dynabeads Protein G (Cat.
No.10003D) as described below. After PBS wash, cells were crosslinked with 1%
formaldehyde (15 min incubation at room temperature) in PBS. The crosslinked cells
were washed thrice in PBS and scraped off the plates in PBS (containing PI), pelleted at
7.5 rcf (10 min, 4ºC). The pelleted cells were lysed in SDS lysis buffer (1% SDS, 10 mM
EDTA, 50 mM Tris-HCl pH 8), incubated on ice for 10 min and subjected to sonication
(sonicator: XL-2000 QSonica LLC) on ice by setting the pulse at 4 for 4-5 times with 1
minute interval in between, followed by centrifugation (14000 rpm, 15 min, 4ºC) to collect
the sonicated clear sheared chromatin lysate. IP was done in this lysate with 30 µl of
Protein G magnetic beads, corresponding antibody (5 µg; control IgG included in a
separate IP) in a total volume of 2 ml (diluted 1:10 with ChIP dilution buffer: 0.01% SDS,
1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl pH 8.1, 167 mM NaCl) overnight
(4ºC) with constant shaking. Next day, the IPs were washed sequentially with low salt
immune complex wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM TrisHCl pH 8, 150 mM NaCl), high salt immune complex wash buffer (0.1% SDS, 1% Triton
X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8, 500 mM NaCl), LiCl immune complex Wash
Buffer (0.25 M LiCl, 1% NP40, 1% Na-deoxycholate, 1 mM EDTA, 10 mM Tris-HCl pH 8)
and TE Buffer (10 mM Tris-HCl, 1 mM EDTA pH 8). The protein-DNA complexes were
eluted in ChIP elution buffer (1% SDS, 0.1 M NaHCO3), de-crosslinked in 200 mM NaCl
for 4 hours at 65ºC. ChIP DNA was purified by RNase treatment, proteinase K digestion,
phenol chloroform extraction, and precipitation by 100% ethanol precipitation using a
standard protocol. The ChIP-purified DNA was finally dissolved in 10 mM Tris-HCl pH 8.
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The ChIP and 1% input DNA were subjected to SYBR GREEN-based Real-Time PCR
(7500 Real-Time PCR System; Applied Biosystems) with primers Table 5. ChIP RT-PCR
data were analyzed using the percent input method and normalized against the control.
In brief, the percent input was calculated as 100 × 2(adjusted input − CT of IP), where
the adjusted input is the CT (threshold cycle) of the input minus the log2 (dilution factor).

Orthotopic Tumor Implantation
All animal studies were performed according to IACUC approved protocols.
Before injection of pancreatic cancer cells into the pancreas of the mice, the cells were
trypsinized, counted, washed twice in 1 × PBS and resuspended at a density of 3 ×
105 cells per 30µl. 3 × 105 cells were injected orthotopically into the pancreas of immune
deficient female nude mice. Panc-1, MIA PaCa-2 and HGC-25 pancreatic cancer cell
lines and their Lfng knockout counterparts were utilized for the study. The orthotopic
tumor study involving HGC-25 pancreatic cancer cell lines, also included two separate
groups which included HGC-25 parental cell lines which were overexpressing Lfng
cDNA and HGC-25 Lfng KO clone 42 expressing Lfng-cDNA. All groups consisted of 810 mice. Tumors were allowed to develop for 5-8 weeks, at which time mice were
sacrificed and tumors measured. In the case of HGC-25 orthotopic tumor studies, the
tumor volumes of the mice were measured using ultrasound. Presence of metastases
was initially assessed based on gross observation during necropsy. Tissues for each
metastatic site and primary tumor were formalin fixed. The UNMC tissue sciences core
facility cut and stained H&E slides for each sample in the experiment. Metastases were
confirmed by microscopy before final scoring. Statistical analysis of differences in tumor
growth was assessed using Student t-test.
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Ultrasound Imaging
Tumor volume was measured using Visual Sonics Vevo 2100 Imaging. Image
acquisitions were performed using the enhanced abdominal measurement package in
the B-mode and 3-D mode settings. Physiological status (ECG, respiration, blood
pressure, and body temperature) of the mice was closely monitored during each image
acquisition session. Mice were imaged weekly starting at 2 weeks post orthotopic tumor
implantation to 5 weeks using ultrasound to monitor the development of the orthotopic
pancreatic cancer xenografts.

Statistical Analysis
Data was analyzed using GraphPad Prism 5.04 software using Student’s ttest or one-way ANOVA with Dunnet’s Multiple Comparison Post-Test or Bonferroni
Post-Test. For all statistical tests, a p-value of <0.05 was considered to be statistically
significant.
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Table 1: Primers for qPCR Based Evaluation of Gene Expression
The table lists the sequences of forward and reverse primers used for evaluating the
expression of specific genes.
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Table 2: Primers for evaluation of Lfng deletion
The table lists all the sequences of forward and reverse primers used for evaluating the
deletion of Lfng catalytic active site using PCR, RT-PCR, and primers used to assess
the efficiency of Lfng targeting CRISPR guides.
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Table 3: CRISPR/Cas9 guides for targeting human Lfng gene
The table lists the sequences of CRISPR Cas9 guides used for targeting the catalytic
active site of Lfng gene.
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Table 4: Conditions used for optimization of immunohistochemical staining
The table lists the positive controls, the antibody concentrations, incubation conditions
and antigen retrieval conditions used to evaluate the immunohistochemical staining of
proteins in tissue specimens.
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Table 5: The table lists the quantitative real-time PCR primers for detecting FoxM1.

62
Table 5

63

CHAPTER III. EXPRESSION OF NOTCH
RECEPTORS, NOTCH LIGANDS AND
NOTCH-RELATED O-LINKED
GLYCOSYLTRANSFERASES IN
PANCREATIC CANCER
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INTRODUCTION
We have discussed the importance of Notch signaling and its glycosylation in the
contexts of development, developmental disorders, and cancer in the previous sections.
Our understanding of the role of Notch-related glycosylation in human pancreatic cancer
is limited. While other studies have characterized the expression of Notch signaling
components in PDAC, a detailed characterization of Notch receptors, its ligands and
Notch-related O-glycosyltransferases in the context of PDAC has not been reported to
date. We sought to characterize the expression of Notch receptors, Notch ligands, and
Notch-related glycosyltransferases in PDAC. We hypothesized that human PDAC
specimens and pancreatic cancer cell lines will have elevated expression of Notch
receptors and ligands. In light of the recent report of the tumor suppressive role of Lfng
in Kras driven pancreatic cancers, we hypothesized that Lfng will have a decreased
expression in PDAC (107). We characterize the expression of Notch receptors, Notch
ligands and Notch-related O-glycosyltransferases in human pancreatic cancer cell lines
using western blotting and quantitative real-time PCR. We assessed the expression of
Notch receptors, Notch ligands and Lfng in human PDAC and normal pancreas
specimens using immunohistochemistry.

RESULTS
Expression of Notch Receptors in Human Pancreatic Cancer Cell
Lines
To assess the endogenous expression of Notch receptors in pancreatic cancer,
we performed western blotting and compared the expression a panel of 5 human
pancreatic cancer cell lines, hTERT-HPNE E6/E7/Kras G12D/st cells and hTERT-HPNE.
hTERT-HPNE cells are derived from pancreas duct while the hTERT-HPNE E6/E7/Kras
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G12D/st cells were originally generated by transfecting the hTERT-HPNE cells with
E6/E7, Kras G12D and SV40 small t (st) antigen (130). The hTERT- HPNE E6/E7/ Kras
G12D/st cells will be referred to as T-HPNE from here forward. Figure 7 presents
western blots that examined the expression of Notch receptors in the panel of human
pancreatic cancer cell lines.
Expression of Notch-1 protein was robust in all pancreatic cancer cell lines
examined. Four out of five human pancreatic cancer cell lines (MIA PaCa-2, T3M4,
PANC-1, and BxPC-3) showed increased expression of Notch-1 expression as
compared to hTERT-HPNE cell lines. Two human pancreatic cancer cell lines T3M4 and
BxPC-3 showed the highest expression of Notch1 among the panel of human pancreatic
cancer cell lines. Also, T-HPNE cells exhibited higher expression of Notch-1 as
compared to hTERT-HPNE cells. These results further support previous findings of
Notch-1 expression in human pancreatic cancer. Notch3 was robustly expressed in all
human pancreatic cancer cell lines. A comparison of the panel of human pancreatic
cancer cell lines and hTERT-HPNE cells revealed that T3M4 cells had higher Notch3
protein expression than hTERT-HPNE cells. Our results also showed that T-HPNE cells
had elevated expression of Notch3 as compared to hTERT-HPNE cells.
We evaluated Notch-2 protein expression in pancreatic cancer cell lines. In
comparison with hTERT-HPNE cells, the panel of human pancreatic cancer cell lines
and T-HPNE cells showed lower levels of Notch-2 expression. Notch4 was expressed at
slightly lower levels as compared to all the other Notch receptors in all the cell lines. Our
results showed only T3M4 and PANC-1 human pancreatic cancer cells had elevated
expression of Notch4 protein as compared to hTERT-HPNE cells. The expression of
Notch4 was similar among HPNE-hTERT, AsPC-1, MIA PaCa-2, BxPC-3 and T-HPNE
cells. Mullendore M. et al. reported that only 4 of 20 human pancreatic cancer cell lines
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had elevated Notch2 mRNA expression as compared to HPNE cells (57). Previous
studies have also reported low mRNA expression of Notch4 in cultured human
pancreatic cancer cells (131).
Thus we conclude that the expression of Notch3, Notch-1 expression was robust
across all pancreatic cancer cell lines and T-HPNE and the expression of other Notch
receptors is heterogeneous in all the 5 human pancreatic cancer cell lines.

Expression of Notch Ligands in Human Pancreatic Cancer Cell Lines
A similar panel of human pancreatic cancer cell lines, hTERT-HPNE cells, and THPNE cells were used to assess the expression of Notch ligands Jagged-1, Jagged-2
and Delta-like ligand-4 by immunoblotting. Our results showed that expression of Notch
ligands Jagged-1 was consistently elevated across all the pancreatic cancer cell lines
included in our panel as compared to hTERT-HPNE cells. Figure 8 presents western
blots showing the expression of Notch ligands in the panel of human pancreatic cancer
cell lines.
Jagged-1 protein expression was elevated in T-HPNE cells as compared to
hTERT-HPNE cells. Dll4 ligand was robustly expressed across all the cell lines
examined. Four out of five human pancreatic cancer cell lines (MIA PaCa-2, T3M4,
PANC-1, and BxPC-3) showed increased expression of Dll4 than HPNE htert cells. We
also saw increased Dll4 protein expression in T-HPNE cells as compared to hTERTHPNE cells. Jagged-2 expression was elevated in three out of five (MIA PaCa-2, T3M4,
PANC-1) human pancreatic cancer cell lines. We could not detect Jagged-2 in AsPC-1
cells. BxPC-3 and T-HPNE cells showed lower levels of Jagged-2 expression as
compared to HPNE cells. These results indicate that Notch ligands Dll4 and Jagged-1
have higher protein expression in pancreatic cancer cells compared to HPNE cells,
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whereas the expression of Notch ligand Jagged-2 was heterogeneous among the panel
of human pancreatic cancer cell lines compared to HPNE cells.

Expression of Notch-Related Glycosyltransferases in Human
Pancreatic Cancer Cell Lines
Given that expression of Notch receptors and ligands was observed in most of
the human pancreatic cancer cell lines examined, we sought to evaluate the expression
of Notch-related glycosyltransferases in the same panel of cell lines. Qualitative realtime quantitative real-time PCR analysis of the panel of 5 human pancreatic cancer cell
lines were compared to hTERT-HPNE cells. We assessed the expression of Notchrelated glycosyltransferases Protein O-fucosyltransferase-1 (Pofut1), Fringe
glycosyltransferases (Lfng, Mfng, Rfng), Protein O-glucosyltransferase-1 (Poglut1), and
glucoside xylosyltransferase genes (Gxylt1, Gxylt2). Variable expression of Notchrelated glycosyltransferases in all human pancreatic cancer cell lines compared to
hTERT-HPNE cells. Two of five pancreatic cancer cell lines (PANC-1 and AsPC-1) had
greater expression of Pofut1 gene, while the other 3 cell lines showed reduced
expression of Pofut1 as compared to hTERT-HPNE cells.
Initially we examined the mRNA expression of Fringe glycosyltransferases in the
panel of human pancreatic cancer cell lines. We observed marked up-regulation in the
transcripts of Fringe glycosyltransferase Lfng in all human pancreatic cancer cell lines as
compared to hTERT-HPNE Figure 9. We observed a nearly 280-fold increase in
expression of Lfng transcripts in AsPC-1 cells as compared to hTERT-HPNE cells, while
human pancreatic cancer cell lines PANC-1 and BxPC-3 showed nearly 25-fold and 31fold increase in Lfng expression respectively. MIA PaCa-2 cell lines showed a modest
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increase of ~ 1.5-fold increase in Lfng transcript expression and T3M4 cells showed an
increase of ~ 2.8 fold increase.
Three of five (PANC-1, MIA PaCa-2, and AsPC-1) human pancreatic cancer cell
lines showed an increase in Rfng expression. AsPC-1 cells showed the highest
expression of Rfng expression compared to hTERT-HPNE cells with nearly 4.5-fold
increase Figure 9. Two of five pancreatic cancer cell lines PANC-1 and AsPC-1 showed
nearly 2-fold and 3-fold increase in Mfng expression while T3M4, MIA PaCa-2, and
BxPC-3 all showed lesser Mfng transcript levels than hTERT-HPNE cells Figure 9.
We examined the mRNA expression of Poglut1, Pofut1, Gxylt1/2 in the panel of
human pancreatic cancer cell lines. Among the panel of human pancreatic cancer cell
lines, only AsPC-1 cells had elevated greater expression of Pofut1 mRNA as compared
to HPNE cells (Figure 10). PANC-1 and BxPC-3 cells did not show any significant
difference in Pofut1 expression. MIA PaCa-2 and T3M4 cell had decreased Pofut1
mRNA expression of Lfng as compared to HPNE cells. PANC-1 cells also showed an
increase in the transcript of Notch-related glycosyltransferases such as Poglut1, Gxylt1,
and Gxylt2. Interestingly, among the panel of 5 pancreatic cancer cell lines, only PANC1 showed elevated levels of Notch-glycosyltransferase Gxylt2 while other pancreatic
cancer cell lines showed transcript levels lower than hTERT-HPNE cells. AsPC-1 cells
also showed almost 2-fold increases in both Poglut1 and Gxylt1 transcript levels. AsPC1 was the only cell line that showed an increase in Gxylt2 transcripts in comparison to
hTERT-HPNE cells; while other human pancreatic cancer cell lines in the panel had
expression equal to or lesser than the hTERT-HPNE cells.
Based on these observations, we conclude that overall expression of Fringe
glycosyltransferase isoforms in human pancreatic cancer cell lines was variable;
however, expression of Lfng was consistently increased in these cell lines. Our results
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did not support the hypothesis that Lfng acts as a tumor suppressor, but do support an
alternative hypothesis that Lfng acts as an oncogene in human PDAC.

Expression of Notch3 and Notch4 in Normal Human Pancreas and
Human Pancreatic Cancer Specimens
Further validation of upregulated Notch signaling proteins in human pancreatic
ductal adenocarcinoma was obtained by immunohistochemical analysis of human
pancreatic cancer specimens. Pancreatic cancer primary tumor specimens from 25
patients, liver metastasis specimens from 19 PDAC patients and normal pancreas from
8 organ donors were assessed by immunohistochemical methods for expression of
Notch3. Similarly, pancreatic cancer primary tumor specimens from 24 patients, liver
metastasis specimens from 19 PDAC patients and normal pancreas from 8 organ
donors were assessed for expression of Notch4. Samples were organized into tissue
microarrays to allow simultaneous staining of multiple specimens. Immunohistochemical
staining conditions including antigen retrieval treatment, antibody concentrations, and
antibody incubation temperature and time were optimized using positive control
specimens as listed in Table 4. The immunohistochemical expression for different
antigens was scored on the basis of percentage cells stained positive on a scale of 0-4
(0-Negatve, 1- <25%, 2- 25% - 50%, 3- 50% - 75%, 4- < 75%). We stratified the
immunohistochemical expression in normal pancreas according to cell type (Acinar or
Ductal cells). The expression in these individual cell types was compared to expression
in tumor cells present in the primary tumors and liver metastases. The average and
median-values of the immunohistochemical expression are listed in Table 6.
Figure 11 presents the immunohistochemical expression of Notch3 in human
pancreatic cancer specimens and normal human pancreas. We found little to no
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expression of Notch3 in normal ductal cells while we found low expression of Notch3 in
acinar cells. We compared the average and median immunohistochemical scores found
in the different cellular compartments of the pancreas. The average scores of Notch3 in
acinar cells and ductal cells in the normal pancreas were 1.38 and 0.45 respectively.
The median scores for Notch3 expression in acinar and ductal cells of the normal
pancreas were 1.5 and 0.13 respectively. In comparison all primary tumor and
metastatic human pancreatic cancer specimens showed moderate to high level staining
for Notch3 expression and the average immunohistochemical staining score was 3.23
and 3.74 in primary tumors and liver metastases respectively. The median
immunohistochemical scores for Notch3 staining in primary tumors and liver metastases
were 3.63 and 4 respectively. Based on these observations we conclude that Notch3
expression is elevated in human pancreatic cancer specimens exhibit increased
expression of Notch3 as compared to both acinar and ductal cells of the normal
pancreas.
Immunohistochemical expression of Notch4 in human pancreatic cancer
specimens and normal human pancreas is shown in Figure 12. We found little to no
expression of Notch4 in ductal cells of normal pancreas, whereas there was low
expression of Notch4 in acinar cells of the human pancreas. The average
immunohistochemical staining scores of Notch4 in acinar and ductal cells of normal
human pancreas were 1.44 and 0.25 respectively. The median immunohistochemical
staining scores for Notch4 staining in acinar and ductal cells of the normal human
pancreas was 1.5 and 0 respectively. In contrast, the average immunohistochemical
staining scores of Notch4 in human pancreatic cancers were 2.41 and 1.11 in primary
tumor specimens and liver metastases respectively. The median immunohistochemical
staining scores of Notch4 in human pancreatic cancers were 2.5 and 1 in primary tumor
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specimens and liver metastases respectively. 20 of 24 primary tumor specimens and 10
of 19 liver metastases tissue specimens stained positive for Notch4. This led us to
conclude that Notch4 expression is low to moderate (defined as a score between 1-3) in
normal acinar cells of the pancreas, primary and metastatic pancreatic cancer
specimens. We also observe a significant (p<0.01) decrease in the
immunohistochemical expression of Notch4 in liver metastases specimens when
compared to primary tumor specimens.

Expression of Jagged-1, Jagged-2 and Delta-Like Ligand 4 Notch
Ligands in Normal Human Pancreas and Human Pancreatic Cancer
Specimens
We assessed the expression of Notch ligands, Jagged-1, Jagged-2 and Dll4 in a
similar panel of pancreatic cancer primary tumors and liver metastases specimens. We
compared the immunohistochemical expression of Notch ligands in pancreatic cancer
specimens with normal pancreas specimens. We found that normal ductal and acinar
cells either did not express Notch ligands or had very low expression. Results comparing
the immunohistochemical expression of Jag1, Jag2, and Dll4 in human pancreatic
cancer specimens and normal human pancreas are represented Figure 13, Figure 14
and Figure 15 respectively.
The average immunohistochemical staining in normal acinar and ductal cells for
Jag1 was 0.5 and 0.38 respectively while their median score in both the cell types was 0.
In comparison, the average immunohistochemical score for Jag1 was 2.72 and 1.47 in
primary tumor and liver metastases respectively. The median scores for Jag1 in primary
tumor specimens and liver metastases were 3 and 1 respectively. Our results indicate
that Notch ligand Jag2 is not expressed in acinar and ductal cells of the normal human
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pancreas. In contrast, Jag2 expression is elevated in the primary tumor and liver
metastases. The average staining scores of Jag2 in primary tumors and liver metastases
is 2.18 and 2.85 respectively. The median scores were 2 and 3 for primary tumor and
liver metastases specimens respectively. 24 of 27 primary tumor specimens stained
positive for Jag2 and 20 of 20 liver metastases specimens stained positive for Jag2
expression. Notch ligand Dll4 was most robustly expressed in human pancreatic cancer
specimens. The average score for primary tumor specimens and liver metastases was
3.42 and 3.60 respectively. The median staining scores were 3.75 and 4 in primary
tumors and liver metastases specimens respectively. Based on these findings, we
conclude that expression of Notch ligands Jag1, Jag2 and Dll4 are significantly elevated
in human pancreatic cancer tumor specimens as compared to expression in cells of the
normal pancreas.

Expression of Hes1 in Normal Pancreas and Human Pancreatic
Cancer Specimens
Hes1, a downstream target of Notch signaling, is often used as an indicator of
Notch signaling activation. Our results indicate that Hes1 expression was elevated in
human pancreatic cancer tumor specimens as compared to the normal human
pancreas. No immunohistochemical expression of Hes1 was observed in ductal cells of
the normal pancreas. Very low Hes1 immunohistochemical expression was observed in
acinar cells. In contrast to the low expression of Hes1 in the normal pancreas, high Hes1
expression was observed by immunohistochemical staining in human pancreatic cancer
specimens. Our findings support previous reports in the literature that suggest increased
Hes1 expression in PDAC. Figure 16 represents the immunohistochemical expression of
Hes1 in human pancreatic cancer specimens and normal human pancreas.
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Expression of Lunatic Fringe Glycosyltransferase in Normal
Pancreas and Human Pancreatic Cancer Specimens
To validate our findings that expression of Notch-related glycosyltransferase
Lfng is elevated in human pancreatic cancer, we performed immunohistochemical
staining on normal pancreas and human pancreatic cancer primary tumor specimens
and liver metastasis specimens. Our results indicate that Lfng expression is low in acinar
and ductal cells of the normal pancreas. The average immunohistochemical score of
Lfng in acinar and ductal cells is 0.44 and 1.06 respectively. The median scores of Lfng
in acinar and ductal cells are 0.5 and 0.75. Lfng is staining was high level in human
pancreatic cancer specimens. The average immunohistochemical score for Lfng in
primary tumor specimens and liver metastases were 3.53 and 4. Both primary tumor
specimens and liver metastases specimens had a median staining score of 4. Based on
these results we conclude that expression of Lfng is significantly (p<0.0001) elevated in
human pancreatic cancer specimens as compared to cells of the normal pancreas. Our
results from immunohistochemistry are in alignment with our quantitative real-time qRTPCR that showed an increase in transcript levels of Lfng in human pancreatic cancer cell
lines. Figure 17 presents the immunohistochemical expression of Lfng in human
pancreatic cancer specimens and normal human pancreas

DISCUSSION
We have evaluated the expression of Notch receptors, Notch ligands and Notchrelated glycosyltransferases in the context of human pancreatic cancer. We examined a
panel of human pancreatic cancer cell lines and human pancreatic cancer specimens for
to characterize the expression of Notch signaling components. Overall, we observed that
Notch receptors and ligands are expressed in both human pancreatic cancer cell lines
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and in human PDAC tissue specimens. We observed that Notch1, Notch3, Jag1, Jag2,
and Dll4 were robustly expressed in human pancreatic cancer cell lines. We observe
elevated immunohistochemical expression of Notch3, Notch4 Jagged1, Jagged2, Dll4,
Hes1 and Lfng in human pancreatic cancer specimens as compared with expression in
normal pancreas. The immunohistochemical expression of Notch3, Notch4, Jag1, Jag2,
Dll4, Hes1 and Lfng in the individual normal pancreas and in primary tumor PDAC
specimens is presented in summary form as a heat map in Figure 18.
In matched liver metastases and primary tumor specimens, the expression of
Notch3 was consistently high as compared to expression in cells of the normal pancreas
(Figure 11). Upregulation of Notch3 has been previously reported in resected human
PDAC specimens (48,131,132). Previous reports have also indicated that elevated
expression of Notch3 and Hey1 is significantly associated with reduced overall survival
and disease-free survival following tumor resection (50). Elevated expression of Dll4,
Jag1, and Jag2 in human PDAC has been previously reported in the literature (133–
135). The elevated expression of Dll4 has been associated with poor prognosis following
tumor resection and gemcitabine response (51,52). We also observed that Jagged2
ligand expression was elevated in liver metastases specimens compared to primary
tumor specimens (Figure 14). Previous reports in the literature have shown that elevated
levels of Jagged2 contribute to increased pancreatic cancer metastases and migration
(135). Our results are in alignment with the previously reports that characterized the
expression of Notch3, Dll4, Jag1 and Jag2 in human PDAC specimens.
Elevated expression of Notch4 receptor in human pancreatic cancer tumor
specimens as compared to normal pancreas has been previously reported (131). We
observed that expression of Notch4 and Jagged1 is lower in PDAC liver metastases
specimens as compared to primary PDAC tumor specimens. Based on the changes in
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immunohistochemical expression of Notch4, Jag1 and Jag2 in the primary tumor and
liver metastasis specimens, we put forward the hypothesis that the expression of the
Notch signaling components may be dynamic in different tumor microenvironments.
Alterations in expression of Notch signaling components may provide a survival
advantage to the tumor cells in different local tumor microenvironments.
We report increased mRNA and immunohistological expression of Lfng in PDAC
cell lines and human PDAC specimens respectively (Figure 9 and Figure 17). These
observations suggest that Lfng does not have a classical tumor suppressor role in
human PDAC as previously reported in the literature (111). Based on the increased
mRNA and immunohistological expression of Lfng observed in PDAC cell lines and
human PDAC specimens respectively, we hypothesize that increased expression of Lfng
contributes to pancreatic cancer tumorigenicity in advanced pancreatic ductal
adenocarcinoma.
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Figure 7: Characterization of Notch Receptors, in Human PDAC Cell Lines.
Western blotting to detect protein expression of Notch receptors (A) Notch-1 (B) Notch-2
(C) Notch3 (D) Notch4 in human pancreatic cancer cell lines, HPNE cells and HPNE-T
cells. 35µg of protein lysate was loaded to each lane. Expression of Notch receptors in
cell lysates was assessed using primary and secondary antibody previously described in
the Materials and Methods section. β-actin was used as a loading control.
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Figure 8: Characterization of Notch Signaling Ligands, in Human PDAC Cell Lines.
Western blotting to analysis was performed to compare the protein expression of Notch
ligands (A) Jag1 (B) Jag2 (C) Dll4 in a panel of human pancreatic cancer cell lines,
HPNE cells and HPNE-T cells. 35µg of protein lysate was loaded to each lane.
Expression of Notch ligands in cell lysates was assessed using primary and secondary
antibody previously described in the Materials and Methods section. β-actin was used as
a loading control.
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Figure 9: Expression of Fringe Glycosyltransferase, in Human PDAC Cell Lines.
Relative expression of mRNA for Fringe glycosyltransferases (A-B) Lfng (C) Mfng (D)
Rfng in human pancreatic cancer cell lines. 100ng of cDNA was used per 50ul
quantitative real-time PCR reaction. mRNA expression levels of all genes are normalized
to 18SRNA and presented as relative expression compared to HPNE cells.
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Figure 10: Pofut1, Poglut1, Gxylt1/2 Expression In Human PDAC Cell Lines.
Relative expression of mRNA for Notch-related O-linked glycosyltransferases (A) Pofut1
(B) Poglut1 (C) Gxylt1 (D) Gxylt2 in human pancreatic cancer cell lines. 100ng of cDNA
was used per 50ul quantitative real-time PCR reaction. mRNA expression levels of all
genes are normalized to 18SRNA and presented as relative expression compared to
HPNE cells.
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Figure 11: Expression of Notch3 in Normal Pancreas and Human PDAC
Specimens.
(A-C) Panel of representative images of Notch3 immunohistochemical expression in (A)
normal human pancreas, (B) primary tumors and (C) liver metastases specimens
obtained from pancreatic cancer patients. (A) White arrowheads indicate the point to the
ductal cells in the pancreas. The inset shows a magnified image of the ductal cells. (D)
The graph represents the immunohistological staining score of Notch3 protein in the
acinar, ductal cell types of normal pancreas, and the cancer cells present in the primary
and liver metastasis sites. One-way ANOVA with Bonferroni post-test was performed to
compare the differences between different groups. P-value of <0.05 was considered as
significant.
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Figure 12: Expression of Notch4 in Normal Pancreas and Human PDAC
Specimens.
(A-C) Panel of representative images of Notch4 immunohistochemical expression in (A)
normal human pancreas, (B) primary tumors and (C) liver metastases specimens
obtained from pancreatic cancer patients. (A) White arrowheads indicate the point to the
ductal cells in the pancreas. The inset shows a magnified image of the ductal cells. (D)
The graph represents the immunohistological staining score of Notch4 protein in the
acinar, ductal cell types of normal pancreas, and the cancer cells present in the primary
and liver metastasis sites. Increase in immunohistological expression of Notch4 was
observed in primary tumor cells as compared to ductal cells of the normal pancreas.
One-way ANOVA with Bonferroni post-test was performed to compare the differences
between different groups. P-value of <0.05 was considered as significant.
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Figure 13: Expression of Jag1 in Normal Pancreas and Human PDAC Specimens.
(A-C) Panel of representative images of Jag1 immunohistochemical expression in (A)
normal human pancreas, (B) primary tumors and (C) liver metastases specimens
obtained from pancreatic cancer patients. (A) White arrowheads indicate the point to the
ductal cells in the pancreas. The inset shows a magnified image of the ductal cells. (D)
The graph represents the immunohistological staining score of Jag1 protein in the
acinar, ductal cell types of normal pancreas, and the cancer cells present in the primary
and liver metastasis sites. One-way ANOVA with Bonferroni post-test was performed to
compare the differences between different groups. P-value of <0.05 was considered as
significant.
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Figure 14: Expression of Jag2 in Normal Pancreas and Human PDAC Specimens.
(A-C) Panel of representative images of Jag2 immunohistochemical expression in (A)
normal human pancreas, (B) primary tumors and (C) liver metastases specimens
obtained from pancreatic cancer patients. (A) White arrowheads indicate the point to the
ductal cells in the pancreas. The inset shows a magnified image of the ductal cells. (D)
The graph represents the immunohistological staining score of Jag2 protein in the
acinar, ductal cell types of normal pancreas, and the cancer cells present in the primary
and liver metastasis sites. One-way ANOVA with Bonferroni post-test was performed to
compare the differences between different groups. P-value of <0.05 was considered as
significant.
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Figure 15: Expression of Dll4 in Normal Pancreas and Human PDAC Specimens.
(A-C) Panel of representative images of Dll4 immunohistochemical expression in (A)
normal human pancreas, (B) primary tumors and (C) liver metastases specimens
obtained from pancreatic cancer patients. (A) White arrowheads indicate the point to the
ductal cells in the pancreas. The inset shows a magnified image of the ductal cells. (D)
The graph represents the immunohistological staining score of Dll4 protein in the acinar,
ductal cell types of normal pancreas, and the cancer cells present in the primary and
liver metastasis sites. One-way ANOVA with Bonferroni post-test was performed to
compare the differences between different groups. P-value of <0.05 was considered as
significant.
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Figure 16: Expression of Hes1 in Normal Pancreas and Human PDAC Specimens.
(A-B) Panel of representative images of Hes1 immunohistochemical expression in (A)
normal human pancreas, (B) primary tumors obtained from pancreatic cancer patients.
White arrowheads indicate the point to the ductal cells in the pancreas. The inset shows
a magnified image of the ductal cells. (C) The graph represents the immunohistological
staining score of Hes1 protein in the acinar, ductal cell types of normal pancreas, and
the cancer cells present in the primary tumor. One-way ANOVA with Bonferroni post-test
was performed to compare the differences between different groups. P-value of <0.05
was considered as significant.

95
Figure 16

96
Figure 17: Expression of Lfng in Normal Pancreas and Human PDAC Specimens.
(A-C) Panel of representative images of Lfng immunohistochemical expression in (A)
normal human pancreas, (B) primary tumors and (C) liver metastases specimens
obtained from pancreatic cancer patients. (A) White arrowheads indicate the point to the
ductal cells in the pancreas. The inset shows a magnified image of the ductal cells. (D)
The graph represents the immunohistological staining score of Lfng protein in the acinar,
ductal cell types of normal pancreas, and the cancer cells present in the primary and
liver metastasis sites. One-way ANOVA with Bonferroni post-test was performed to
compare the differences between different groups. P-value of <0.05 was considered as
significant.

97
Figure 17

98
Figure 18: Heat map Showing Relative Immunohistochemical Staining in Cells of
the Normal Pancreas and Primary Tumor Specimens of Human PDAC specimens.
The labels on top indicate the heat map indicate the type of sample (Normal pancreas
tissue or the Rapid Autopsy Patient). Each column represents a unique sample and
each row represents a different protein. The labels on the left of the heat map indicate
the protein that was assessed. Heat map was generated using conditional formatting
function of Microsoft Excel. Each box represents the average immunohistochemical
staining score for a particular protein in that tissue sample. The immunohistochemical
scores are represented as a color gradient between black and red. Black indicated no
immunohistochemical staining and increasing intensity of red indicates the increasing
immunohistochemical expression of Notch signaling proteins in tissue specimens.
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Table 6: Summary of Immunohistochemical Staining in the Normal Pancreas and
Human PDAC Tumor Specimens
The table indicates the average and median immunohistological scored for different
Notch3, Notch4, Jag1, Jag2, Dll4, Hes1 and Lfng in cells of the normal pancreas,
primary tumors and liver metastases specimens from PDAC patients. The average and
median statistics were achieved using the column statistics function in the Prism
GraphPad Prism software.
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CHAPTER IV. GENERATION OF
MODEL SYSTEMS TO STUDY LFNG
IN PANCREATIC CANCER
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INTRODUCTION
Lfng is a glycosyltransferase enzyme (136). Our findings from the
immunohistochemical staining and quantitative real-time PCR revealed that Lfng is
elevated in human pancreatic cancer. We sought to generate a pancreatic cancer cell
line based model using a loss of function approach to further investigate the role of Lfng
in human pancreatic cancer cell lines. While RNAi technology offers a quick and
efficient method to interrogate the function of a gene in cell lines, it may not highlight the
effects resulting from complete loss-of-function of Lfng gene. Hence, to further
interrogate the role of Lfng in PDAC we made use of TALEN and CRISPR/Cas9 genome
editing nucleases to design Lfng KO human pancreatic cancer cell lines for studying the
role of Lfng in pancreatic cancer.
TALEN-based Approach to Delete LFNG in Human Pancreatic Cancer Cell Lines
In our initial approach to target Lfng gene in human pancreatic cancer cell lines,
we designed TALENs to introduce genomic deletion in the Lfng gene and knockin a Tdtomato reporter gene construct at the site of genomic deletion. However, in our hands,
we were unable to generate the Lfng KO human pancreatic cancer cell lines using
TALEN based genome-editing technology. Our unsuccessful attempts at generating Lfng
KO human pancreatic cancer cell lines using a TALEN-based approach for generating
could have been as a result of multitude of reasons including, lack of enrichment of cells
that were successfully transfected with the TALEN constructs, poor cutting efficiency at
Lfng target site or non-specific homologous recombination of reporter donor gene
construct leading to increased number of false positive. After unsuccessful attempts in
deletion of Lfng in human pancreatic cancer cell lines, we revised our approach and
switched to CRISPR/Cas9-based gene editing.
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CRISPR/Cas9-mediated Genome Editing
The ability to edit the genome of an organism using programmable
endonucleases at a cellular level has tremendous biotechnological, healthcare and basic
science applications (137). The emergence of genome editing nuclease such as
TALENs, Zinc Finger Nucleases (ZFN), Meganucleases and clustered regularly
interspaced short palindromic repeats (CRISPR) facilitate efficient genome engineering
in eukaryotic cells (138). Recent advances in CRISPR technology have eased the
generation of genetic knockout and knockin in cell lines and mice. The CRISPR/Cas9
technology allows us to investigate the function of a gene in different model systems
(cell lines or animals) with relative ease.
CRISPR-Cas9 works as a two-part system with the CRISPR-RNAs providing the
target specificity and the Cas9 protein acting as a genome editing nuclease. The
CRISPR-Cas9 system was initially discovered as a bacterial and archaeal immune
mechanism (139). These organisms use this system to store the DNA fragments from
the invading viruses into their genome. Upon subsequent attack by these viruses, the
bacteria would transcribe the CRISPR sequences into CRISPR RNAs (crRNAS) to guide
the Cas9 protein to cleave the DNA or RNA from the invading species and thus protect
the host species (140).The crRNAs rely on the presence of protospacer-adjacent motif
(PAM) sequence next to the target genome in the genome of the invading species
(141,142).The absence of PAM sequence in the host genome prevents the CRISPRCas9 complex from targeting the host genome (137). This CRISPR-Cas9 system was
repurposed to effectively mediate genome targeting in a wide variety of organisms. The
Cas9 protein from Streptococcus pyogenes (Sp) is most commonly used for genome
engineering. The SpCas9 utilizes a PAM sequence of NGG, where N can be any
nucleotide and GG represent the two-guanine bases.
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The Cas9 protein contains an HNH nuclease domain and a RuvC-like nuclease
domain. The HNH nuclease domain cuts the target strand of the DNA while the RuvC
like nuclease targets the nontarget strand of the DNA that is complementary to the target
strand. The CRISPR Cas9 technology functions by stimulating a double stranded break
(DSB) at the target genomic locus using the Cas9 and the crRNA. The cell then repairs
the DSB via either Non-homologous end joining (NHEJ) or homology directed repair
(HDR). The NHEJ is often utilized generate gene knockout as it is an error-prone repair
mechanism during which the DSB are repaired with insertion/deletion (indel) mutations
(143,144). Indels are defined as insertion or deletion of nucleotide bases in the genome
of the organism. These indels occurring within the coding region of the gene can often
result in a frameshift mutation and introduce a premature stop codon (124).
CRISPR/Cas9 can be utilized to generate multiple DSB in the genome to delete larger
genomic deletions (125).
The Cas9 protein has also been modified to produce variants that can introduce
a single-stranded nick in the site-specific manner. The nickase variants of Cas9 (nCas9)
were generated by mutating one of the two nuclease domains of the Cas9 proteins,
rendering one of them inactive. Two nCas9 targeted to the adjacent strands of the DNA
can also be utilized to introduce a DSB. These have been shown to increase the
specificity of the Cas9 mediated targeting of the genome (144–146). Mutating both the
nuclease domains of Cas9 render the Cas9 protein devoid of any nuclease activity while
maintaining its RNA-guided DNA binding activity intact. This allows the dCas9 to
mediate site-specific genetic regulation. The CRISPR-Cas9 based gene-editing
technological platform is now broadly used to understand the function of genes in
various disease model systems (9,10) This technology offers a simple way of generating
genetic changes in model systems in a short duration of time. We have made use of
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CRISPR/Cas9-mediated genome editing approach to design cell line based model
systems to study the role of Lfng in pancreatic cancer. The double stranded break
introduced by Cas9 protein is typically repaired by error-prone NHEJ. Simultaneous
introduction of two DSBs can be used to generate larger genomic deletions. NHEJ DNA
repair mechanisms results in deletion of genomic regions between the two DSBs. We
used a similar approach to delete the catalytic active site of Lfng in its gene.
Generation of Lfng flox/flox; LSL-KrasG12D/+; TP53R172H/+
Previous reports in the literature mention a tumor suppressive role of Lfng in Kras
driven pancreatic cancer using a pancreas-specific mutant Kras Lfng knockout mouse
model. To understand the role of Lfng in the genetically engineered mouse models for
advanced PDAC we designed Lfng flox/flox; LSL-KrasG12D/+; TP53R172H/+. Lfngflox mice were
obtained from Mutant Mouse Research and Research Centers (MMRRC# 37160). Pdx1Cre, LSL-KrasG12D/+ and TP53R172H/+ have been previously described (5). All the mouse
lines are available through Jackson laboratories, Pdx1 Cre, stock No: 014647, LSLKrasG12D stock No: 008179 and LSL-Trp53R172H stock No: 008652. These mice were
interbred to produce the Lfng flox/flox; LSL-KrasG12D/+; TP53R172H/+.

RESULTS
Cutting Efficiency of CRISPR/Cas9 Guides using Surveyor Assay
The cutting efficiency of individual CRISPR guides we designed for Lfng were
evaluated by Surveyor assay. The double stranded break introduced by Cas9 protein is
typically repaired by error-prone NHEJ. The NHEJ repair process results in indel
formations, which are small insertions or deletions at the break site. The efficiency of
indel mutations resulting from the different Lfng targeting guides was detected by PCR
amplification of the target site using genomic DNA. The conditions for PCR amplification
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of the CRISPR targeted Lfng region was optimized (Figure 19 A). The PCR products
were denatured and allowed to hybridize. The products were incubated in Surveyor
nuclease that detects mismatches in DNA and cleaves them. The percentage of
targeting by the CRISPR guides was calculated using image analysis of polyacrylamide
gels as previously described (124). PANC-1 cells were transfected with either Lfng
targeting CRISPR guides that were cloned into a px458 plasmid or empty plasmid. DNA
was isolated 48 hrs. post transfection and the Surveyor assay were performed. We did
not detect any gene modification in cells transfected with control plasmid, whereas
significant modification was detected in all the cells treated with Lfng targeting
CRISPR/Cas9 plasmids. Our results showed that the guide 1 targeting the exon 7 of
Lfng gene had an indel efficiency of 5% compared to control reaction, whereas CRISPR
guide 2 targeting the exon 7 of Lfng gene had an indel efficiency of 9.6% (Figure 19B).
These results suggested that CRISPR guide 2 had 1.98-fold targeting efficiency at exon
7 of Lfng gene as compared to the CRISPR guide 1. Based on our findings we selected
CRISPR guide 2 targeting exon 7 of Lfng gene for our studies.

PCR-based Screening of CRISPR-Edited Human PDAC Cell Lines
The CRISPR/Cas9 can be used to mediate larger deletions in the genome of the
cells. We made use of PCR-based screening strategy to detect the cells in which
CRISPR Cas9 mediated genome editing resulted in deletion of genomic sequences
encoding the Lfng catalytic active. We optimized the conditions for PCR amplification of
the genomic DNA around the sites of CRISPR-mediated deletions.
We then tested the proficiency of the paired CRISPR/Cas9 system by cotransfecting with pairs of CRISPR Cas9 plasmids that targeted before and after the Lfng
catalytic active site. These transfections were performed on HEK-293T and PANC-1
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cells. Our results indicated that co-transfection of individual guides targeting sites before
and after the Lfng catalytic active site did not reveal any deletions in PANC-1 cells,
whereas HEK-293T cells showed microdeletions based on PCR analysis (Figure 20).
These results suggested that transfection of co-transfection of individual CRISPR guides
into the cells can effectively result in microdeletions, however their efficiency can vary
depending on the degree of co-transfection or cell type-dependent factors.
To address whether the lack of microdeletions in PANC-1 cells was due to a
lesser degree of co-transfection in PANC-1 human pancreatic cancer cells, we utilized
Multiplex CRISPR/Cas9 toolkit. We modified the existing plasmids by cloning in -2A-GFP
from the px458 vector into px330A Multiplex vectors using FseI and NotI unique
restriction sites (Figure 21). Our results indicate that expression of GFP reporter gene
and the multiplex CRISPR Cas9 vector together resulted in better enrichment of
CRISPR targeted cells in human PDAC cell lines Figure 22. We screened 283 single cell
clones using PCR-based screening and found that 79.51% of cells were had
heterozygous deletion of Lfng catalytic active site, whereas 10.95% of PANC-1 cells had
homozygous deletion of Lfng catalytic active site. The efficiency of CRISPR/Cas9
mediated deletion of Lfng catalytic active site are listed in Table 7. These results
indicate that using modified Multiplex-2A-GFP enables us to enrich for CRISPR
transfected cells in which microdeletion of Lfng catalytic site had occurred.
Using this modified multiplex CRISPR-2A-GFP plasmid; we were able to screen
MIA Paca-2 and HGC-25 human pancreatic cancer cell lines in which Lfng catalytic
active site was deleted. Our results indicate that the efficiency of homozygous deletion of
Lfng in MIA PaCa-2 and HGC-25 human pancreatic cancer cell line was 14.29% and
20.59% respectively. The efficiency of heterozygous deletion of Lfng catalytic active site
was 45.71% and 41.18% in MIA Paca-2 and HGC-25 human pancreatic cancer cell lines
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respectively. The genomic DNA PCR screen for detecting the CRISPR/Cas9-mediated
deletion of Lfng is shown in Figure 23.

Sequencing of CRISPR/Cas9-mediated Deletion Boundaries of Lfng
using Sanger Sequencing.
To identify the boundaries of NHEJ in homozygously deleted Lfng KO human
pancreatic cancer cell lines, we gel purified the PCR product from the genomic DNA
screen. The PCR products were sequenced by Eurofins Genomics. The sequence
analysis of these PCR products revealed that in both PANC-1 and MIA PaCa-2 Lfng KO
clones had the same boundaries of NHEJ after CRISPR-mediated deletion.
Furthermore, sequencing analysis revealed that Clone 25 Lfng KO had an additional
deletion of single base pair adenosine at the NHEJ boundary. HGC-25 Lfng KO clones 2
and 56 had multiple sequences after the NHEJ boundary suggesting the possibility of
multiclonal populations. Although these cells have multiclonal populations, all contained
a complete deletion of the Lfng catalytic active site as shown by the by truncated PCR
product in the PCR based screen for detecting Lfng KO cells. The result from Sanger
sequencing of PANC-1 and MIA PaCa-2 Lfng KO clones and parental human pancreatic
cancer cell lines are listed in Figure 24.

Validation of Lfng KO in Human PDAC Cell Lines using RT-PCR
To validate that CRISPR/Cas9 mediated knockout of the Lfng catalytic active site
results in loss of the codons that translate to Lfng catalytic active residues, we performed
the RT-PCR analysis. RNA was isolated using Trizol reagent and reverse transcribed to
cDNA. We designed unique primer sets such that the forward primer annealed to the
CRISPR deleted region of Lfng cDNA while the reverse primer annealed outside the
CRISPR targeted region of the Lfng cDNA. We optimized the optimal annealing
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temperature conditions for primer amplification using a gradient PCR. The RT-PCR
results revealed that in control cancer cells there was robust PCR amplification of the
Lfng catalytic active site while no amplification was observed in Lfng KO cancer cells
(Figure 25). β-actin was used as a positive control to serve as a control for the quality of
cDNA.
We also designed another set of qPCR primers that span the exon junctions of
exon 5, exon 6 and exon junctions of exon 8, exon9. As expected, we observed that
cDNA from homozygous Lfng KO human pancreatic cancer cell lines had a truncated
PCR product while control pancreatic cancer cells had a complete amplification of PCR
product (Figure 26). Furthermore, heterozygous Lfng KO human pancreatic cancer cells
showed amplification of truncated as well as complete amplification of PCR product.

GFP-Tagged Lfng Expression in MIA PaCa-2 and HGC-25 Human
Pancreatic Cancer Cell Lines
To validate that phenotypic effects observed in human pancreatic cancer cell
lines were due to specific deletion of Lfng, we made use of green fluorescent protein
(GFP)-tagged Lfng cDNA construct to perform rescue experiments. We expressed Lfng
GFP-tagged Lfng cDNA into parental and Lfng KO human pancreatic cancer cell lines.
To validate the level of exogenous Lfng expression in MIA PaCa-2 and MIA
PaCa-2 Lfng KO cells we used qRT-PCR. Our results show that MIA PaCa-2 cells and
MIA PaCa-2 Lfng KO clone 1 cells showed a robust increase in Lfng transcript
expression, when lentivirally transduced with GFP tagged Lfng cDNA plasmid Figure 27.
Furthermore, we validated the compartmental localization of exogenous Lfng in the cells.
We used immunofluorescence staining to validate the localization of the Lfng protein in
these cells. Lfng is a glycosyltransferase enzyme, which is localized in the Golgi
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complex. We used Giantin as a marker for Golgi complex. Our results show that GFP
tagged Lfng colocalized with Giantin in HGC-25 human pancreatic cancer cell lines
(Figure 28B). This suggests that exogenously expressed Lfng is localized in the Golgi
complex. Western blotting using anti-GFP antibody we validated the protein expression
of exogenous GFP-tagged Lfng in HGC-25 cells (Figure 28A). These results suggest
that we were able to achieve a robust expression of GFP-tagged LFNG results in the
Golgi complex of human pancreatic cancer cell lines.

Expression and Purification of His-tagged Wild-Type Lfng and HisTagged CRISPR-Edited Lfng
Previous reports have shown that aspartic acid residue D288 is responsible for
the catalytic activity of the Lfng enzyme. Mutation of D288 results in abrogation of
catalytic activity of the Lfng enzyme. We wanted to generate wild-type and CRISPRedited Lfng isoforms and evaluate the impact of CRISPR-mediated deletion of the Lfng
catalytic active site on the catalytic activity of the enzyme.
We cloned the sequences for wild-type Lfng and CRISPR-edited Lfng into
psectag2 expression vectors. CHOK1 cells were transfected with psectag2 wild-type
Lfng and psectag2 CRISPR-edited Lfng separately. Figure 29B represents a
confirmation of secreted Lfng proteins using western blotting. Although we were able to
detect the presence of His-tagged wildtype and CRISPR-edited proteins in the cell
culture supernatant, we could not achieve purification of sufficient proteins to perform
radiolabeled enzyme assay Figure 29A.

DISCUSSION
We were able to generate and validate the homozygous deletion of the Lfng
catalytic active site in three human pancreatic cancer cell lines. Previous reports have
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illustrated that multiplex CRISPR/Cas9 plasmid can greatly increase the efficiency of
targeting multiple areas in the genome simultaneously. In our hands, we observed that
targeting two regions of the Lfng gene in PANC-1 cells using Multiplex CRISPR/Cas9
construct had a greater efficiency of generating genomic deletion as compared to
targeting with individual CRISPR/Cas9 constructs. We are able to modify the existing
CRISPR/Cas9 multiplex vectors with GFP reported construct to enrich for CRISPR/Cas9
transfected cells. Using the modified multiplex CRISPR/Cas9 construct we were able to
successfully isolate pancreatic cancer cell line clones in which Lfng catalytic active site
was deleted. We were also able to generate Lfng flox/flox; LSL-KrasG12D/+; TP53R172H/+
mice to interrogate the role of Lfng deletion in advanced pancreatic cancer mouse
model.
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Figure 19: Surveyor Assay Analysis for CRISPR Guides.
The CRISPR/Cas9 mediated cutting efficiency was assessed using Surveyor nuclease
assay. (A) Optimization of the PCR amplification condition for the Lfng specific surveyor
assay primers. (B) Cutting efficiency of the CRISPR/Cas9 guide was assessed using
PCR products from untreated (No CRISPR/Cas9 transfection), Lfng exon7 targeting
CRISPR guide 1 and Lfng exon7 targeting guide 2. Reactions were run on a DNA gel
and indel frequency was assessed using densitometry analysis.

114
Figure 19

115
Figure 20: Deletion of Lfng Catalytic Active Site by Cotransfection of Lfng
Targeting CRISPR Guides
(A) Non-homologous end joining mediated deletion of the Lfng catalytic active site was
assessed by using PCR primers flanking the Lfng catalytic active site. Dashed lines
indicate the approximate site of CRISPR mediated deletion. Blue arrows indicate the
forward and reverse primer used for assessing the CRISPR mediated NHEJ at the Lfng
catalytic active locus. (B) Assessment of NHEJ mediated deletion of Lfng catalytic active
site in PANC-1 and HEK-293T cells transfected with plasmid coding individual exon and
intron targeting guide.
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Figure 21: Generation of 2A-GFP Multiplex CRISPR Vectors
(A) px458 CRISPR/Cas9 2A-GFP plasmid and Multiplex CRISPR px330A plasmids were
restriction digested using FseI and NotI restriction enzymes (B) Assessment of
successful ligation of 2A-GFP DNA sequence into the Multiplex px330A 1X2 by
restriction digestion using FseI and NotI restriction enzymes.
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Figure 22: Efficiency Deletion of Lfng Catalytic Active Site by Cotransfection of
Lfng Targeting CRISPR Exon and Intron Guides
(A) A pair of CRISPR guides specifically targeting the Lfng catalytic active site were
cloned into the px330 1X2 CRISPR multiplex plasmid modified with the 2A-GFP plasmid.
Cells were imaged at a100X magnification using fluorescence microscope. (B) Specific
deletion of the Lfng catalytic active site was verified using PCR.
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Table 7: Efficiency of Lfng Catalytic Active Site Deletion using 2A-GFP-Modified
Multiplex CRISPR/Cas9 Plasmid in Pancreatic Cancer Cell Lines.
Percent efficiency of CRISPR/Cas9 mediated deletion of the Lfng catalytic active site in
human pancreatic cancer cell lines.

122
Table 7

123
Figure 23: Assessment of CRISPR/Cas9-Mediated Deletion of the Lfng Catalytic
Active Site in Human Pancreatic Cancer Cell Lines using PCR.
Genomic DNA PCR-based screening for CRISPR mediated homozygous deletion of
Lfng catalytic active site deletion in (A) MIA PaCa-2 cells (B) PANC-1 cells (C) HGC-25
cells. The greater PCR product in the genomic DNA of parental cells is indicative of no
deletion. The smaller PCR product is indicative of CRISPR/Cas9-mediated deletion of
Lfng catalytic active site in single cell clones of corresponding human pancreatic cancer
cells.
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Figure 24: Boundary of CRISPR-Mediated Non-Homologous End Joining in the
Lfng Gene Locus.
Sanger sequencing results for the genomic region around the Lfng catalytic active site in
PANC-1, MIA PaCa-2 Parental cell lines and their corresponding CRISPR treated Lfng
knockout clones. The nucleotides highlighted in red indicate the codons for catalytic
active aspartic acid residue. The nucleotides highlighted in blue and green are the sites
of double stranded breaks mediated by Lfng targeting CRISPR/Cas9. Double stranded
breaks at these sites (highlighted by blue and green nucleotides) result in NHEJ and loss
of the Lfng catalytic active site. Sequences were validated by Sanger sequencing.
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Figure 25: Validation of CRISPR-Mediated Deletion of the Lfng Catalytic Active
Site in Human Pancreatic Cancer Cell Lines using RT-PCR Based Strategy.
Homozygous deletion of the Lfng catalytic active site was further validated using RTPCR. (A) The dashed lines indicate the approximate location of CRISPR-mediated
deletion in the Lfng gene locus. The red arrows indicate the approximate region where
RT-PCR primers bind on the cDNA. Validation of the homozygous deletion of the Lfng
catalytic active site using RT-PCR in (B) MIA PaCa-2 cells (C) PANC-1 cells (D) HGC-25
cells.
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Figure 26: Validation of CRISPR-Mediated Deletion of the Lfng Catalytic Active
Site in Human Pancreatic Cancer Cell Lines using RT-PCR Based Strategy.
Homozygous deletion of the Lfng catalytic active site was validated in PANC-1 cells
using RT-PCR. (A) The dashed lines indicate the approximate location of CRISPR/Cas9
mediated deletion in the Lfng gene locus. The blue arrows indicate the approximate
region where RT-PCR primers bind on the cDNA. (B) Optimization of primer annealing
temperature using gradient annealing PCR. (C) RT-PCR based validation of
CRISPR/Cas9 mediated deletion of the Lfng catalytic active site.
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Figure 27: Exogenous Expression of P-Lenti-Lfng GFP in PANC-1 and MIA PaCa-2
Human Pancreatic Cancer Cell Lines.
Quantitative real-time PCR comparing the relative expression of exogenous Lfng cDNA
in (A) MIA PaCa-2 parental cells, MIA PaCa-2 Lfng KO clone 1 cells and (B) PANC-1
parental cells. Gene expression of exogenous Lfng cDNA was normalized to 18S RNA.
All quantitative real-time PCR reactions were performed using SYBR green as
previously described in the materials and methods. 50ng of cDNA was used for every
25µl q-RT PCR reaction.
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Figure 28: Expression of P-Lenti-Lfng GFP in HGC-25 Pancreatic Cancer Cell
Lines.
(A) Protein expression was detected with an anti-GFP antibody on whole cell lysates
from a panel of HGC-25 cell lines in which GFP-tagged Lfng was ectopically expressed
using lentiviral transduction. Western blot shows restoration of Lfng expression in HGC25 Parental and HGC-25 Lfng KO clone 25 and HGC-25 Lfng KO clone 42. B-actin was
used as a loading control. (B) Immunofluorescence images represent the co-localization
of empty GFP-tag vector (top) and the GFP-tagged Lfng protein (bottom) with Golgi
marker Giantin (red). HGC-25 Lfng KO clone 25 cells transduction with GFP-tagged Lfng
cDNA localized in the Golgi compartment of the cells.
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Figure 29: Expression of Wild-type and CRISPR-Edited Lfng in CHOK1
CHOK1 cells were transfected with psectag2 vectors driving the expression of His
tagged wild-type Lfng or CRISPR-edited Lfng. Cell culture supernatant was purified
using His Pure beads which bind to his tagged proteins. 50 µl of eluted protein was
loaded on to a SDS PAGE gel and stained with SimplyBlue SafeStain to visualize the
purified His-tagged proteins. (A) His-tagged Lfng wild-type (Left) and CRISPR-edited
Lfng proteins (right) The arrows point to the weak purification of wild-type and CRISPRedited Lfng. (B) Western blot analysis for detection of wild-type Lfng and CRISPR/Cas9edited Lfng protein in cell culture supernatant using anti-His tag antibody. Forty
microliters of cell culture supernatant from CHOK1 cells transfected with psectag2
vectors driving the expression of wild-type and CRISPR-edited His tagged protein was
loaded on to a SDS PAGE gel. The western blot detects a higher molecular weight wildtype His-tagged Lfng and a lower molecular weight His-tagged CRISPR/Cas9-edited
Lfng.
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CHAPTER V. ELUCIDATING THE ROLE OF
NOTCH-RELATED
GLYCOSYLTRANSFERASE LFNG IN
PANCREATIC CANCER
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INTRODUCTION
The importance of Notch-related glycosylation in modulating Notch-receptor
ligand interaction has been well documented in developmental, and diseased conditions
in the literature (147). Based on a previous report in the literature suggesting the tumor
suppressor activity (111), our initial hypothesis was that Lfng expression would be
downregulated in human pancreatic cancer cell lines and in human pancreatic cancer
tumor specimens. In contrast to this hypothesis, our IHC and quantitative real-time PCR
results show that expression of Lfng is elevated in human pancreatic cancer (Chapter
III). Lfng mediated glycosylation has been shown to modulate Notch receptor ligand
interaction and Notch signaling. Increased Notch signaling activation has been shown to
contribute to increased cell proliferation, and disease progression in pancreatic cancer.
Hence, we revised our hypothesis to reflect that Notch-related
glycosyltransferase was upregulated in advanced human PDAC and instead proposed
that Lfng contributes to tumorigenicity by modulating the oncogenic Notch signaling in
pancreatic cancer. To further investigate the role of Lfng in pancreatic cancer we
generated Pdx1-Cre Lfng flox/flox; KRASG12D; TP53 R172H and Lfng KO human pancreatic
cancer cell lines as described in Chapter IV.
Using the KPC GEMM for advanced PDAC cancer, we evaluated the impact of
pancreas specific deletion of Lfng on overall survival in the mouse. We also evaluated
the effect of Lfng KO on in vitro and in vivo cell proliferation properties of human
pancreatic cancer cell lines and noticed a possible metabolite phenotype during in vitro
cell culture. While cancer has long been thought as a disease characterized by abnormal
cell proliferation, advances in the fields of transcriptomics and cancer metabolomics over
the last decade have led to a change in this perspective. Metabolic reprogramming is
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now considered one of the hallmarks of cancer (148). Previous studies in the field have
also shown that Notch signaling is involved in metabolic reprogramming (149–151).
Given that Lfng modulated Notch receptor ligand interaction and signaling activation, we
wanted to extend the scope of our study to understand the effects of deletion of Lfng
catalytic active site on metabolic reprogramming in human pancreatic cancer cells. We
used LC-MS based metabolite profiling, to evaluate the changes in the global metabolic
profile of human pancreatic cancer cell lines in presence and absence of Lfng functional
Lfng. We used Lfng KO human pancreatic cancer cell lines and their respective parental
controls to assess the changes in metabolite profile as a result of deletion of Lfng.
In summary, we found that deletion of Lfng modulated cell and tumor growth in
the KPC GEMM and human pancreatic cancer cell line models, albeit in different ways.
We observed that in both the models deletion of Lfng was able to impact the PDAC
tumorigenicity. Our results also show that deletion of Lfng in human pancreatic cancer
resulted in metabolic reprogramming.

RESULTS
Deletion of Lfng in Pdx1 KRASG12D TPP53 R172H Background
Reduces Overall Survival
The Kaplan Meier survival curve shown in Figure 30 compares the survival
curves of wild-type Lfng KPC mice and Lfng KO KPC mice. Our analysis showed that
pancreas specific deletion of Lfng in KrasG12D R172H background resulted in
significantly decreased overall survival. The median survival for Lfng KO KPC and Lfng
het KPC mice was 84 days and 116 days, respectively. Lfng wild-type KPC control mice
had a median survival for 170 days. These results suggest that deletion of Lfng in
GEMM for pancreatic cancer results in decreased overall survival. These results support
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a tumor suppressive role previously reported for Lfng effects on the KC strain of mice
(111), and extends these findings to the KPC strain. These results also stand in contrast
to our previous observation of elevated expression of Lfng in human PDAC specimens
and in human pancreatic cancer cell lines (Figure 9A and Figure 17). The fact that Lfng
and Notch are not highly expressed in adult pancreas cells (Chapter III) but are reexpressed in cancer suggests that Notch and Lfng effects are highly context dependent.
Thus, it was important to further explore the effects of inactivating Lfng in established
cancers; we elected to characterize the impact of deletion of Lfng catalytic active site in
three human pancreatic cancer cell lines (PANC-1, MIA PaCa-2, and HGC-25)

Deletion of Lfng Catalytic Active Site Alters Notch Receptor-Ligand
Binding Activity in Human PDAC Cell Lines
We used a previously described flow cytometry-based Notch ligand binding
assay to study the changes in Notch ligand binding upon deletion of Lfng from human
pancreatic cancer cell lines (127). We used Dll4-Fc and Jag1-Fc soluble ligands to test
the effect of deletion of Lfng catalytic active site on ligand binding affinity. Human
pancreatic cancer PANC-1 and MIA PaCa-2 were used to test the effect of deletion of
Lfng on the Notch receptor-ligand binding. We previously discussed the generation and
validation of Lfng KO human pancreatic cancer cell lines (

CHAPTER IV.

GENERATION OF MODEL SYSTEMS
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TO STUDY LFNG IN PANCREATIC
CANCER)
We found that CRISPR/Cas9 mediated deletion of Lfng catalytic active site
resulted in a significant (p-value < 0.001) decrease in Dll4 ligand binding in human
pancreatic cancer cell lines (Figure 31). Thus, our findings support evidence previously
reported in the literature that Lfng activity affects the specificity of Notch ligand
interactions and extends these observations to human pancreatic cancer cell lines.
Similar effects of Fringe glycosyltransferases on Delta like ligand have been consistently
reported by several other groups (92,93). We also report that deletion of Lfng catalytic
active site results in a heterogeneous effect on Jag ligand binding. We observed that
CRISPR/Cas9 mediated deletion of Lfng in PANC-1 pancreatic cancer cells resulted in a
significant decrease in Jag1 ligand binding in two of three Lfng KO clones (Figure 32C).
One PANC-1 Lfng KO clone did not show any significant change in Jag1 ligand binding
compared to the control cells. Lfng deletion in MIA PaCa-2 human pancreatic cancer cell
lines resulted in a significant (P < 0.05) decrease in Jag1 ligand binding in both clones
compared to the MIA PaCa-2 control cell lines (Figure 32).
Previous studies have shown that addition of N-acetylglucosamine (GlcNAc) to
the O-fucose on epidermal growth factor (EGF) repeats of the Notch extracellular
domains (NECD) by fringe glycosyltransferase enhanced Notch signaling mediated by
Delta ligands such as Dll1 and Dll4 while reducing signaling induced by Jagged ligands
Jag1 and Jag2 (82,136,152). Other groups have previously reported that modification of
the O-fucosylated Notch receptor with GlcNAc by Fringe glycosyltransferase enhanced
Notch receptor-Delta ligand interactions (92,93). Recent reports have suggested that
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Fringe mediated glycosylation of Notch receptors enhanced ligand binding of both Deltalike and Jag ligands, however the presence of Fringe mediated glycosylation inhibits Jag
mediated Notch signaling activation (92,93). The inhibition of Jag mediated Notch
signaling enforced by Fringe modification of Notch receptors is suggested to occur
because of mechanisms downstream of Notch receptor-ligand interaction (92). Based on
our observations we conclude that CRISPR-mediated deletion of Lfng decreased Notch
receptor-ligand interactions to Dll4 and Jag1 ligands in human pancreatic cancer cell
lines.

Effect of Deletion of Lfng on Expression of Notch Receptors, Notch
Ligands and Hes1
We studied the impact of CRISPR/Cas9 mediated deletion of Lfng in human
pancreatic cancer cell lines on Notch receptor and ligand protein expression in MIA
PaCa-2 (Figure 33) and PANC-1 cells (Figure 34). We observed that deletion of Lfng
resulted in an overall decrease of Notch1 and Notch-4 protein expression in MIA PaCa-2
cells. We also observed an increase in Notch-3 protein expression in MIA PaCa-2 Lfng
knockout cells lines as compared to MIA PaCa-2 parental cell lines. In PANC-1 cells,
deletion of Lfng resulted in increased Notch-2, Notch-4 protein expression as compared
to control cells. No changes were observed for Notch-3 expression in PANC-1 and their
corresponding Lfng KO cell lines. We observed heterogeneous expression of Notch-1
protein between the PANC-1 Lfng KO clones as compared to parental PANC-1 human
pancreatic cancer cells. Protein expression of Jag1 Jag2 and Dll4 was consistently
elevated in both MIA PaCa-2 (Figure 33 E-G) and PANC-1 Lfng KO cells (Figure 34 EG) as compared to their corresponding parental controls.
Deletion of Lfng catalytic active site in MIA PaCa-2 cells resulted in a robust
increase in Hes1 mRNA and protein expression (Figure 35A and Figure 35C). PANC-1
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Lfng KO cells showed a modest increase in mRNA expression in two out of three LFNG
KO clones however, we did not observe any consistent change in Hes1 protein
expression in these cells compared to PANC-1 parental cells (Figure 35B and Figure
35D).
In conclusion, our results suggest that deletion of Lfng catalytic active site leads
to increased expression of Notch ligands Jag1, Jag2 and Dll4. Deletion of Lfng in MIA
PaCa-2 cells resulted in a robust increase in Hes1 mRNA and protein expression. While
deletion of Lfng in PANC-1 cells resulted in a modest increase in two of the Lfng KO
clones, we did not observe any consistent differences in Hes1 protein expression. We
observed that deletion of Lfng in human pancreatic cancer cell lines altered Notch
receptor protein expression in cell line-dependent manner.

Deletion of Lfng Reduces In Vitro Cell Proliferation in Human PDAC
Cell Lines
Cancer is characterized by abnormal cell proliferation (148). The results from the
Lfng KO KPC GEMM suggested that Lfng deletion decreased overall survival (Figure
30). We hypothesized that if Lfng is indeed a classical tumor suppressor, deletion of Lfng
in human pancreatic cancer cell lines would result in increased in vitro cell proliferation.
To assess the effect of deletion of LFNG on the proliferative properties of pancreatic
cancer cell lines, we monitored the cell proliferation between wild-type and LFNG KO
pancreatic cancer cell lines over 120 hours at 24-hour intervals. Methylene blue cell
proliferation assays were utilized to assess the effect of Lfng KO on cell proliferation in
PANC-1, MIA PaCa-2 human pancreatic cancer cell lines. Alamar Blue cell viability
assay was utilized to assess the effect of Lfng KO on the in vitro cell proliferation of
HGC-25 cells.
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Deletion of LFNG catalytic active site resulted in a significant (p<0.001) decrease
in cell proliferation of MIA PaCa-2 (Figure 37A), PANC-1 (Figure 38) and HGC-25
(Figure 39A) cells. We also show that, lentiviral-mediated re-expression of exogenous
LFNG cDNA in MIA PaCa-2 LFNG KO clone 1 and HGC-25 LFNG KO cells resulted in a
significant (p<0.001) rescue of in vitro cell proliferation defects (Figure 37B and Figure
39B). Lentiviral expression of LFNG cDNA in MIA PaCa-2 and HGC-25 wild-type
pancreatic cancer cell lines resulted in a significant (p<0.001) increase in cell
proliferation as compared to parental MIA PaCa-2 and HGC-25 cells Figure 37B and
Figure 39B, respectively. These results suggest that Lfng does not act like a classical
tumor suppressor in human pancreatic cancer cell lines.
Consistent with our findings, another group has previously reported that siRNAmediated knockdown of Lfng in PANC-1 cells resulted in decreased in vitro cell
proliferation (111). In the same study, shRNA-mediated LFNG knockdown in MIA PaCa2 cells resulted in an overall increase in vitro cell proliferation. These findings are in
contrast to our observations in MIA PaCa-2 cells. These differences in findings could be
a result of the degree of LFNG suppression achieved in the two studies. In our studies,
we achieve a complete knockout of Lfng expression, whereas the shRNA mediated
knockdown resulted in a partial knockdown of Lfng expression. The varying degrees of
Lfng expression may account for the differences in the in vitro cell proliferation observed
in the two studies.
Our results provide strong evidence that genetic deletion of LFNG catalytic active
site in three different human pancreatic cancer cell lines results in a significant (p<0.001)
decrease in in vitro cell proliferation. Exogenous expression of LFNG in pancreatic
cancer cells rescues the proliferation defects resulting from deletion of the catalytic
active site of LFNG.
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Deletion of Lfng Reduces In Vivo Tumorigenicity in Human Pancreatic
Cancer Cell Lines
Having established that deletion of LFNG catalytic active site in human
pancreatic cancer cell lines resulted in decreased in vitro cell proliferation, we next
evaluated the effect of deletion of LFNG catalytic active site on tumor growth in vivo in
immunodeficient mice following orthotopic implantation of wild-type and LFNG KO
pancreatic cancer cell lines. Consistent with our in vitro findings and in contrast to our
Lfng KO KPC GEMM model findings, significant decreases in tumor volume were
observed in LFNG KO MIA PaCa-2 and PANC-1 pancreatic cancer cell lines compared
to their parental counterparts (Figure 40, Figure 41).
We investigated further the effect deletion of LFNG active site on in vivo growth
properties of pancreatic cancer cells. HGC-25 human pancreatic cancer cell line and its
LFNG KO counterparts were orthotopically implanted into the pancreas of nude mice.
Ultrasound tumor volume measurements were obtained once every week starting from 2
weeks post orthotopic tumor implantation to week 5 weeks post tumor implantation.
Figure 42A shows a representative ultrasound tumor volume measurement for mice
implanted with HGC-25 parental and HGC-25 LFNG KO cells. There was a significant
decrease in tumor volume in mice in which LFNG catalytic active site was deleted
(Figure 42B). Furthermore, re-expression of LFNG-cDNA in HGC-25 LFNG KO Clone 42
rescued the in vivo tumorigenicity defects due to CRISPR-mediated deletion of LFNG
(Figure 43).
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Deletion of Lfng Reduces Metastatic Spread of Human PDAC Cell
Lines In Vivo
We investigated the effect deletion of Lfng KO catalytic active site on the
metastatic spread of disease in vivo. Spleen, lung, diaphragm, and liver were harvested
from the mice 6 weeks post orthotopic implantation of PANC-1, MIA PaCa-2 human
pancreatic cancer cell lines and their corresponding Lfng KO clones (Figure 44).
A comparison of metastatic profile of MIA PaCa-2 Lfng KO tumors and MIA
PaCa-2 parental control tumors is shown in Figure 44A. We observed decreased
metastatic spread to spleen, liver and diaphragm in all the mice injected with Lfng KO
MIA PaCa-2 cells a compared with mice injected with MIA PaCa-2 cells. Forty percent (4
of 10) of all the mice injected with MIA PaCa-2 parental cells, 20% (2of 10) of MIA PaCa2 Lfng KO clone1, 20% (2 of 10) of MIA PaCa-2 Lfng KO Lfng KO clone 2 had
pancreatic cancer invasion in the spleen. None of the 20 mice injected with Lfng KO MIA
PaCa-2 mice from the two Lfng KO clones had any liver or diaphragm involvement,
whereas 20% (2 of 10) of all the mice injected with MIA PaCa-2 parental cells had liver
metastases while 40% (4 of 10) had diaphragm metastases. Interestingly, while no mice
in control group had lung metastases, 10% of the mice (1 of 10) had metastases to the
lung in mice injected with MIA PaCa-2 Lfng KO clone 1. We conclude that deletion of
Lfng in PANC-1 and MIA PaCa-2 human pancreatic cancer cell lines reduces the overall
metastatic process and burden in vivo.
A comparison of the metastatic profile of PANC-1 Lfng KO tumors and PANC-1
parental control tumors is shown in Figure 44B. We observed decreased metastatic
spread to spleen and lungs in all the mice injected with Lfng KO PANC-1 cells. Seventyfive percent (6 of 8) of all the mice injected with PANC-1 parental cells, twenty-five
percent (2 of 8) of Lfng KO clone 1, 12.5% (1 of 8) of Lfng KO clone 2, and fifty percent
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(4 of 8) of Lfng KO clone 3 had pancreatic cancer invasion in spleen. Out of all the mice
injected with PANC-1 parental cells, 42.85% (3 of 7), 25% (2 of 8) of Lfng KO clone 1,
12.5% (1 of 8) of Lfng KO clone 2, and 12.5% (1 of 8) of Lfng KO clone 3 had metastatic
spread to lungs. Twenty-five percent (2 of 8) of all mice injected with PANC-1 parental
cells had liver metastases. Two of three PANC-1 Lfng KO clones (Clone 2 and Clone 3)
showed decreased metastases to the liver, while one Lfng KO clone (clone 1) showed
25% metastases to liver. Surprisingly, none of the mice injected with PANC-1 parental
cell lines had metastases to diaphragm while two of three Lfng KO PANC-1 clones
showed metastases to the diaphragm (25% and 37.5%).
In summary, that deletion of Lfng catalytic active site human pancreatic cancer
cell lines results in an overall decrease in in vitro cell proliferation and in vivo
tumorigenicity. Together these results suggest that Lfng does not behave as a classical
tumor suppressor in human pancreatic cancer cell lines as previously reported (111).

Deletion of Lfng Impacts Gene Expression Profile of Human
Pancreatic Cancer Cell Lines
Notch signaling is an intercellular cell communication pathway and activation of
Notch signaling activation results in translocation of NICD into the nucleus, followed by
transcription of genes (153,154). The mode of Notch signaling activation is previously
described in Chapter I. Given the ability of Notch signaling pathway to induce changes in
the transcriptional profile of cells, we decided to elucidate the effect of Lfng deletion on
the transcriptional changes in human PDAC cell lines. Using RNA sequencing we
compared the transcriptional profile of PANC-1 and MIA PaCa-2 Lfng KO clones with
their corresponding parental cell lines.
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Our results showed that several genes were differentially expressed in human
pancreatic cancer cell lines upon CRISPR/Cas9 mediated deletion of Lfng. A Venn
diagrams depicting the number of genes that are significantly downregulated and
upregulated in MIA PaCa-2 and PANC-1 human pancreatic cancer cell lines are shown
in Figure 45A and Figure 45B respectively. The heat maps of genes whose expression
was downregulated and upregulated in MIA PaCa-2 and PANC-1 human pancreatic
cancer cell lines upon CRISPR-mediated deletion of Lfng are represented in Figure 45C
and Figure 45D respectively.
These results show that deletion of Lfng has a significant impact on the
transcriptional profile of human pancreatic cancer.

Validation of Target Genes in the RNA Sequencing Data using QPCR
We validated the expression of candidate genes that were differentially
expressed in human pancreatic cancer cell lines following CRISPR mediated Lfng
deletion: Oligophrenin 1 (OPHN1), Pim-1 Proto-Oncogene (PIM1), Thymidylate
Synthetase (TYMS), and BCL2 Like 11 (BCL2L11).
OPHN1 transcript levels were shown to be significantly upregulated in both
PANC-1 and MIA PaCa-2 Lfng KO cells as compared to their corresponding parental
controls. Using quantitative real-time PCR we validated the increased expression of
OPHN1 transcripts in human pancreatic cancer cell lines upon CRISPR/Cas9-mediated
deletion of Lfng. MIA PaCa-2 Lfng KO showed a 3.7-fold and 2.4-fold increase in
OPHN1 transcripts as compared to MIA PaCa-2 pancreatic cancer cell lines Figure 46A.
Similarly, OPHN1 transcripts increased 2.4-fold, 3.1-fold, and 3.6-fold in PANC-1 Lfng
KO clones as compared to PANC-1 parental cell line Figure 46B.
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Our RNA sequencing data showed decreased PIM1 transcripts in Lfng KO
human pancreatic cell lines compared to parental pancreatic cancer cell lines. PIM1 is a
proto-oncogene that encodes a serine/threonine kinase. This protein had been
implicated to be involved in cell cycle progression, apoptosis, and transcriptional
activation in several cancers including prostate cancer, acute myeloid leukemia, and
other hematological disorders. MIA PaCa-2 Lfng KO clones showed a 3.3-fold and 1.39fold decrease in PIM1 expression compared to MIA PaCa-2 parental cells (Figure 47A).
CRISPR/Cas9 mediated deletion of Lfng showed in over 3-fold decrease in PIM1
transcript levels in PANC-1 cells (2 of 3 clones) (Figure 47B). PIM1 mRNA expression
was decreased in both Lfng KO clones (PANC-1 and MIA PaCa-2) according to our RNA
sequencing data. Our quantitative real-time PCR results validated the observations from
our RNA sequencing data.
Interestingly our RNA sequencing data showed decreased Thymidylate
synthetase (TYMS) transcripts in Lfng KO human pancreatic cell lines compared to
parental pancreatic cancer cell lines. TYMS is a biosynthetic enzyme that is crucial for
maintaining thymidine monophosphate levels in the cell. Our quantitative real-time PCR
results showed that transcript levels of TYMS were decreased by at least 1.5-fold (1.5fold to 2-fold decrease among PANC-1 Lfng KO clones compared to parental PANC-1
cells). MIA PaCa-2 Lfng KO cells also exhibited a 4.7-fold and 1.6-fold decrease in
decrease in TYMS transcript levels compared to MIA PaCa-2 parental cells Figure 48.
Our quantitative real-time PCR results validate the observations from our RNA
sequencing data.
BCL2L11 gene expression in MIA PaCa-2, PANC-1 pancreatic cancer cells, and
their corresponding Lfng KO cells. Our results indicate that BCL2L11 gene expression is
elevated in Lfng KO cells as compared to their parental controls Figure 49.
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Deletion of Lfng Reduces Cav1 Gene Expression
RNA sequencing revealed that caveolin genes (Cav1 and Cav2) were among the
list of genes whose expression was downregulated in human pancreatic cancer cell lines
following the deletion of Lfng Figure 45C. Previously, deletion of Lfng in a mammaryspecific manner in a breast cancer mouse model was shown to result in genomic
amplification of Met/Cav gene locus, inducing basal-like and claudin-low tumors (155).
Given the previously established relationship between Lfng and Cav1, we evaluated the
expression of Cav1 in human pancreatic cancer cell lines and their corresponding Lfng
knockout cell lines. Our results showed that Cav1 transcript levels are reduced in Lfng
KO human PDAC cells as compared to control human PDAC cell lines (Figure 50 A-B).
Protein expression of Cav1 was also decreased in Lfng KO human PDAC cell line as
compared to parental human PDAC cell lines Figure 50 C-D.

CRISPR/Cas9-mediated Deletion of Lfng Reduces Notch1ICD
Localization to FoxM1 Gene.
We sought to elucidate the mechanism by which deletion of Lfng regulates Cav1
expression in human pancreatic cancer cell lines. Previous studies in preclinical models
of pancreatic cancer have shown that Cav1 and forkhead transcription factor FoxM1
correlated directly in pancreatic cancer (156). Given the role of Lfng in regulating Notch
receptor ligand interaction in pancreatic cancer cell lines, we investigated whether
deletion of Lfng also resulted in changes in the Notch intracellular domain (NICD)
localization at the FoxM1 gene. We performed chromatin immunoprecipitation (ChIP)
using chromatin prepared from MIA PaCa-2, PANC-1, their corresponding Lfng KO cell
lines and Notch intracellular domain (NICD) antibody to investigate the levels NICD
localization to FoxM1 gene. We evaluated the binding of NICD to three regions of FoxM1
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gene, which have been previously characterized for RBPJ binding, a known DNA
binding partner of NICD (157). Our results showed that deletion of Lfng in pancreatic
cancer cell lines decreased the NICD localization to FoxM1 gene in both PANC-1
(Figure 51 B-C) and MIA PaCa-2 (Figure 51 D) pancreatic cancer cell lines. The
decrease in NICD localization correlated with a decrease in FoxM1 expression in MIA
PaCa-2 (Figure 51 E) and PANC-1 (Figure 51 F) pancreatic cancer cell lines as
evaluated using qPCR. Our results thus indicate that deletion of Lfng decreases NICD
localization to FoxM1 gene thereby decreasing FoxM1 expression.

Deletion of Lfng Affects the Metabolic Profile of Human PDAC Cell
lines
To determine if deletion of Lfng induced differential metabolic changes in human
pancreatic cancer cell lines, we performed LC-MS/MS-based metabolomics analysis of
polar metabolite extracts from PANC-1, MIA PaCa-2 human pancreatic cancer cell lines
and their corresponding Lfng KO clones. MetaboAnalyst tools were used to perform
unsupervised hierarchical clustering analysis of the datasets. A heat map shows the
output of relative metabolite analysis from the MIA PaCa-2 and PANC-1 human
pancreatic cancer cell lines and their corresponding Lfng KO cells (Figure 52 A-B). Every
row in the heat map presents individual metabolites, whereas each column represents a
technical replicate (three technical replicates). The red, green, and black colors are
indicative of the relative abundance of each metabolite within a sample. The scale bar
represents the color intensity. The dendrograms on top of the figure indicates that the
Lfng KO human pancreatic cancer cell lines and parental human pancreatic cancer cell
lines possess different metabolic profiles, and the replicates are tightly clustered
together.
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Further analysis of the polar metabolite data was performed using Partial least
square discriminant analysis (PLS-DA). PLS-DA plots of the polar metabolites show that
the human pancreatic cancer cell lines had metabolite profiles that were different from
the control cell lines. The PLS-DA plots for MIA-PaCa-2 and PANC-1 cells indicate
greater variation between the different groups (indicated by Component 3) of the
samples than within the individual groups (indicated by Component 1) of the samples
(Figure 52 C-D).
Pathway impact analysis of the data from metabolomics revealed that
metabolites in the several biosynthetic pathways were significantly affected upon
deletion of Lfng catalytic active site in MIA PaCa-2 and PANC-1 pancreatic cancer cell
lines. Interestingly, we found significantly decreased levels of metabolites in the
nucleotide biosynthetic pathway in Lfng KO pancreatic cancer cell lines relative to the
parental pancreatic cancer cell lines (Figure 53). Glycolysis pathway results in the
synthesis of glucose-6-phosphate (G6P), Fructose-bis-phosphate (FBP) and
phosphogluconate (PG) which are important metabolic intermediates that are utilized for
the synthesis of nucleotides (158,159). Similarly, metabolites in the pentose phosphate
pathway are essential for generating metabolic intermediates that are utilized for
nucleotide biosynthesis. These include 6-PG, ribose 5-phosphate (R-5P) and
phosphoribosyl pyrophosphate (PRPP) that feed into the nucleotide biosynthesis
pathway (158,159). The pathway impact analysis revealed that deletion of Lfng in human
pancreatic cancer cell lines resulted in decreased metabolites in the glycolysis pathway
and pentose phosphate pathway (Figure 53). The relative mono-, di-, and triphosphate
nucleotide levels are reduced in Lfng KO MIA PaCa2 and Lfng KO PANC-1 human
pancreatic cancer cell lines as compared to the corresponding parental controls.
Relative levels of metabolites in the glycolytic and pentose phosphate pathway were
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also significantly decreased in LFNG KO MIA PaCa2 and Lfng KO PANC-1 human
pancreatic cancer cell lines compared to parental pancreatic cancer cell lines.
Based on these results we conclude that deletion of Lfng in PANC-1 and MIA
PaCa-2 human pancreatic cancer cell lines resulted in decreased nucleotide
biosynthesis in human pancreatic cancer cell lines. These results support our
observation that deletion of Lfng catalytic active site in PANC-1 and MIA PaCa-2 human
pancreatic cancer cell lines contributed decreased cell proliferation in part possibly
through a metabolic reprogramming of human pancreatic cancer cell lines.

DISCUSSION
Our results in the GEMM indicate that deletion of Lfng in KPC background results
in decreased overall survival (Figure 30). These results are in agreement with the
previous reports in which Lfng deletion decreased overall survival in pancreas specific
KrasG12D Cre (KC) mice and suggests a tumor suppressor role of Lfng in these model
systems. In contrast, CRISPR/Cas9-mediated deletion of Lfng catalytic active site in
three human pancreatic cancer cell lines (PANC-1, MIA PaCa-2 and HGC-25) resulted
in an overall decrease in in vitro cell proliferation and in vivo tumorigenicity (Figure 35 Figure 43). These findings together with the fact that Lfng is expressed at low levels in
the normal pancreas and is significantly elevated in human PDAC tumor specimens
(Figure 17) suggest that Lfng is not a classical tumor suppressor gene. The differences
in findings between Lfng KO KPC GEMM mouse model and human tumors may result in
part from the fact that the Pdx1 Cre driver for KC and KPC mouse lines cause
deletion/recombination events in the total pancreas of mice starting at embryonic day
8.5. This raises the possibility that embryonic deletion of Lfng gene in this model system
may impact cell fate or other factors during pancreatic development that enhance the
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activity of activated Kras and mutation of p53 at early stages of pancreatic development,
which in turn accelerates tumorigenesis in this model system.
S. Zhang et al. reported heterogeneous effects on cell proliferation upon
knockdown of Lfng in PANC-1 and MIA PaCa-2 cells (111). The differences in the in
vitro cell proliferation profile of human pancreatic cancer cell lines could be a result of
the degree of Lfng loss of function achieved via shRNA and CRISPR/Cas9 systems. In
our studies, we observed that exogenous expression of Lfng in human pancreatic cancer
cell lines was able to rescue the cell proliferation defects observed in human pancreatic
cancer cell lines due to Lfng deletion. If Lfng is truly a classical tumor suppressor then
exogenous expression of Lfng should have resulted in a decreased cell proliferation.
Synthesis of nucleotides is essential for regulating important cellular processes
such as synthesis of DNA, RNA, regulating cell proliferation and DNA damage response
(159). Biosynthesis of nucleotides is driven by de novo biosynthesis or salvage pathway
(160). Pentose phosphate pathway and glycolysis are both feeder pathways, which
synthesize necessary building blocks for nucleotide biosynthesis (159). Aberrations in
nucleotide metabolism have been previously reported to contribute to a wide variety of
human diseases including cancer (161,162), gout (163), kidney disorders (164) and
defects in the nervous system (165,166). Nucleotide metabolism has been shown to play
a crucial role in the processes of transformation and progression of cancer. Cancer cells
have an increased proliferative capacity which needs to be matched by an increased
nucleotide synthesis requirement (148,167), Cancer cells often achieve increased
intracellular pools of nucleotides through increased activity of nucleotide synthetic
enzymes coupled with lower activity of nucleotide degrading enzymes (168). Cancer
cells have altered nucleotide profile compared to normal cells and hence targeting this
pathway is a lucrative option for cancer therapy.
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We observed alterations in the pentose phosphate pathway, glycolysis pathway,
and purine/pyrimidine biosynthesis upon Lfng deletion in human pancreatic cancer cell
lines (Figure 53). Closer examination of the relative metabolite revealed that expression
of the nucleotides, we found that expression of di- and tri-nucleotide phosphates were
significantly decreased in parental pancreatic cancer cell lines and their respective Lfng
KO cell lines. Glycolysis pathway metabolic intermediates were reduced upon deletion of
Lfng in human pancreatic cancer cell lines (Figure 56). Further assessment of the
relative expression of metabolites in the pentose phosphate pathways revealed that
intermediate metabolites of pentose phosphate pathway such as PRPP and 6phosphogluconate (6-PG) were consistently decreased in Lfng KO pancreatic cancer
cell lines compared to their parental control cell lines (Figure 57). PRPP is a key
precursor that is essential for purine biosynthesis. Thus, reduced nucleotide pools in the
LFNG KO pancreatic cancer cell lines could result from decreased metabolite in PPP
and glycolysis pathways. The decreased metabolite pools were correlated with the
proliferation defects observed in the Lfng KO pancreatic cancer cell lines. Tricarboxylic
acid (TCA) pathway metabolites were mostly unaffected in the Lfng KO pancreatic
cancer cell lines suggesting that the TCA cycle may not compensate for the reduced
levels of ATP in Lfng KO human pancreatic cancer cell lines (Figure 58). The molecular
mechanisms through with Lfng alters the metabolic flux of human pancreatic cancer cell
lines will be the part of the future studies in the laboratory.
Whether Lfng mediates the shift in metabolites in pancreatic cancer cell lines by
directly modulating Notch signaling in pancreatic cancer cell lines or through indirect
cross talk mechanisms with other oncogenic pathways that are known to mediate
metabolic reprogramming in cancer cells remains to be the elucidated. Further
investigation into these areas will provide better insights into how Lfng mediates
metabolic reprogramming in pancreatic cancer.
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How does the loss of Lfng alter the metabolic phenotype in pancreatic cancer cell
lines? Does aberrant expression of Lfng in pancreatic cancer enforce the metabolic
changes directly via Notch signaling or through cooperation with other signaling
pathways? Since Lfng is known to mediate Notch receptor-ligand interaction specificity,
which specific Notch receptor-ligand interaction contributes to this metabolic shift in
pancreatic cancer? All of these are questions are key in addressing the role of Lfng in
PDAC.
Notch signaling has been shown to modulate the cellular processes by altering
the transcriptional profile of cells (153,154). We show that CRISPR/Cas9 mediated
deletion of Lfng catalytic active site also results in alterations in transcriptional profile of
human pancreatic cancer cell lines. Our results suggest that elevated expression of Lfng
in human pancreatic cancer cell lines helps facilitates Notch-related transcriptional
changes in human pancreatic cancer cell lines that impacted tumor growth properties.
Our findings suggest that that in advanced human PDAC tumors increased expression
of Lfng contributes to tumorigenicity through increased cell proliferation and metabolic
reprogramming.
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Figure 30: Deletion of Lfng in Pdx1-Cre Kras G12D TP53 R172H Background
Results in Decreased Overall Survival.
Kaplan-Meier plots comparing the overall survival of Lfng KO KPC mice (n=12) and with
KPC mice (n=41). The graph was generated using GraphPad Prism. Comparison of
survival curves using log-rank (Mantel Cox) test revealed a significant difference
between the two survival curves (p-value < 0.0001)
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Figure 31: Dll-4 Ligand Binding Assay.
CRISPR/Cas9 mediated deletion of Lfng catalytic active site reduces Dll4-Fc ligand
binding in MIA PaCa-2 and PANC-1 PC cell lines. IgG-Fc binding served as a control for
non-specific binding. Representative flow cytometry profiles of Dll-4-Fc binding to (A)
MIA PaCa-2 (B) PANC-1 and their respective Lfng KO clones. Flow cytometer profiles
with solid outline indicate Dll-4 Fc binding profile in parental PC cells and dashed outline
profile indicates Dll-4 Fc binding profile in Lfng KO cells. Average of median
fluorescence intensity (MFI) of 10,000 cells per sample was plotted for (C) PANC-1 and
(D) MIA PaCa-2 cells and compared to their respective Lfng KO clones. Data are the
mean + SD, n=3; * represents P > 0.0001 Student’s t test.
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Figure 32: Jagged 1 Ligand Binding Assay.
CRISPR/Cas9 mediated deletion of Lfng catalytic active site reduced Jagged1-Fc ligand
binding in MIA PaCa-2 and PANC-1 PC cell lines. IgG-Fc binding served as a control for
non-specific binding. Representative flow cytometry profiles of Jagged-1-Fc binding to
(A) MIA PaCa-2 (B) PANC-1 and their respective Lfng KO clones. Solid outline indicates
Jagged1-Fc binding profile in parental PC cells and dashed outline profile indicates
Jagged-1-Fc binding profile in Lfng KO cells. Average of median fluorescence intensity
(MFI) of 10,000 cells per sample was plotted for (C) PANC-1 and
(D) MIA PaCa-2 cells and compared to their respective Lfng KO clones. Data are the
mean + SD, n=3; * represents P > 0.05 Student t-test, *** represents P > 0.001 Student t
test, and *** represents P > 0.0001 Student t-test.
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Figure 33: Notch Receptor and Ligands Expression in MIA PaCa-2 Parental and
Their Corresponding Lfng KO Clones.
Western blot analysis was carried out to compare Notch receptors and Notch ligands in
control MIA PaCa-2 parental cells and MIA PaCa-2 Lfng KO cells. Western blot analysis
was performed using whole cell lysates obtained from parental pancreatic cancer cells
and their corresponding Lfng KO clones. Primary and secondary antibodies used for
Notch receptors and Notch ligands are described in the antibodies and peptide section
of materials and methods. Each well was loaded with 35µg protein lysate. Western blot
analysis was performed using to compare the expression of (A) Notch1 (B) Notch2 (C)
Notch3 (D) Notch4 (E) Jag1 (F) Jag2 (G) Dll4 in MIA PaCa-2 cells and their
corresponding Lfng KO cells. β-actin was used to evaluate protein loading in gels.
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Figure 34: Notch Receptor and Ligands Expression in PANC-1 Parental and Their
Corresponding Lfng KO Clones.
Western blot analysis was carried out to compare Notch receptors and Notch ligands in
control PANC-1 parental cells and PANC-1 Lfng KO cells. Western blot analysis was
performed using whole cell lysates obtained from parental pancreatic cancer cells and
their corresponding Lfng KO clones. Primary and secondary antibodies used for Notch
receptors and Notch ligands are described in the antibodies and peptide section of
materials and methods. Each well was loaded with 35µg protein lysate. Western blot
analysis was performed using to compare the expression of (A) Notch1 (B) Notch2 (C)
Notch3 (D) Notch4 (E) Jag1 (F) Jag2 (G) Dll4 in PANC-1 cells and their corresponding
Lfng KO cells. β-actin was used to evaluate protein loading in gels.
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Figure 35: Hes1 Expression in Pancreatic Cancer Cells and Their Corresponding
Lfng KO Clones.
Quantitative real-time PCR for Hes1 comparing the relative expression of Hes1 gene in
(A) MIA PaCa-2 (B) PANC-1 cell lines and their corresponding Lfng KO cells.
Quantitative real-time PCR was performed described using SYBR green reagent as
described in Materials and Methods. Expression level of Hes1 mRNA is normalized to
18SRNA and presented as relative expression compared to the corresponding parental
cell line. All reactions were carried out using 50ng of cDNA per 25µl qPCR reaction. (CD) Western blot analysis was carried out to compare Hes1 protein expression in MIA
PaCa-2, PANC-1 and their control Lfng KO cells. Western blot analysis was performed
using whole cell lysates obtained from parental pancreatic cancer cells and their
corresponding Lfng KO clones. Primary and secondary antibodies used for Hes1 are
previously described in the antibodies and peptide section of materials and methods.
Each well was loaded with 35µg protein lysate. β-actin was used to evaluate protein
loading in gels.
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Figure 36: Expression of Mfng and Rfng in Human Pancreatic Cancer Cells and
Their Corresponding Lfng KO Clones
Quantitative real-time PCR was performed to assess the increased expression of Mfng
and Rfng. Deletion of Lfng catalytic active site in (A) MIA PaCa-2 and (B) PANC-1 cells
was associated with an increased mRNA expression of Mfng. (C) Deletion of Lfng
catalytic active site in MIA PaCa-2 cells was also associated with an increased mRNA
expression of Rfng. For quantitative real-time PCR, the Mfng and Rfng gene expression
was normalized to 18sRNA gene expression in that sample. In the graph *** represent
p<0.0001 was obtained by Students-t test.
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Figure 37: In Vitro Cell Proliferation Assay Comparing MIA PaCa-2 Human
Pancreatic Cancer Cell Lines and Their Corresponding Lfng KO Clones.
Effects of Lfng deletion on cell proliferation of MIA PaCa-2 human pancreatic cancer cell
lines. As described in the materials and methods section cell proliferation was estimated
by methylene blue colorimetric assay. Methylene blue staining was assessed at 2, 24,
48, 72, 96 and 120 hours after plating cells. Absorbance was measured at 650nm. (A)
Comparison of in vitro cell proliferation between MIA PaCa-2 and their Lfng KO
counterparts. Deletion of Lfng in MIA PaCa-2 cells results in significant decrease in cell
proliferation. (B) Comparison of cell proliferation profiles following exogenous expression
of Lfng cDNA in MIA PaCa-2 parental cell lines and Lfng KO MIA PaCa-2 cells.
Exogenous expression of Lfng cDNA in MIA PaCa-2 parental and Lfng KO clone 1 cells
result in significant increased cell proliferation compared to their corresponding controls.
Data is represented as mean + SEM. ***, p<0.001.
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Figure 38: In vitro Cell Proliferation Assay Comparing PANC-1 Human Pancreatic
Cancer Cell Lines and Their Corresponding Lfng KO Clones.
Effects of Lfng deletion on cell proliferation on PANC-1 human pancreatic cancer cell
lines. As described in the materials and methods section cell proliferation was estimated
by methylene blue colorimetric assay. Methylene blue staining was assessed at 2, 24,
48, 72, 96 and 120 hours after plating cells. Absorbance was measured at 650nm.
Deletion of Lfng in PANC-1 cells results in significant decrease in cell proliferation as
shown in three PANC-1 Lfng KO clones. Data is represented as mean + SEM. ***,
p<0.001.
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Figure 39: In vitro Cell Proliferation Assay Comparing HGC-25 Human Pancreatic
Cancer Cell Lines and Their Corresponding Lfng KO Clones.
Effects of Lfng deletion in HGC-25 human pancreatic cancer cell lines. As described in
the materials and methods section Alamar blue assay was performed to compare the
cell proliferation between different cell lines. Fluorescence measurements were
performed at 2, 24, 48, 72, 96 and 120 hours after plating cells. (A) Comparison of in
vitro cell proliferation between HGC-25 human pancreatic cancer cells and their Lfng KO
counterparts. Deletion of Lfng in HGC-25 cells results in significant decrease cell
proliferation as compared to parental HGC-25 cells. (B) Comparison of cell proliferation
profiles following exogenous expression of Lfng cDNA in HGC-25 parental cell lines and
Lfng KO HGC-25 cells. Exogenous expression of Lfng cDNA in HGC-25 parental and
Lfng KO clone cells results in significant increased cell proliferation compared to their
corresponding controls. Data is represented as mean + SEM. ***, p<0.001.
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Figure 40: Deletion of Lfng Catalytic Active Site Via CRISPR/Cas9 Inhibits In Vivo
Tumorigenicity of MIA PaCa-2 Human Pancreatic Cancer Cell Lines.
MIA PaCa-2 and their corresponding Lfng KO clones (3 X 105 cells) were implanted
directly into the pancreas of 5-6 week-old female nude mice. Mice were sacrificed and
tumors were harvested after 6 weeks post orthotopic tumor implantation. Measurements
of tumor volumes were collected using manual calipers. Quantification of tumor volumes
generated from orthotopic implantation of MIA PaCa-2 and corresponding CRISPR/Cas9
mediated Lfng knockout clones. Data is represented as mean + SEM. **, p<0.01, n=11.
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Figure 41: Deletion of Lfng Catalytic Active Site Via CRISPR/Cas9 Inhibits In Vivo
Tumorigenicity of PANC-1 Human Pancreatic Cancer Cell Lines.
PANC-1 and their corresponding Lfng KO clones (3 X 105 cells) were implanted directly
into the pancreas of 5-6 week-old female nude mice. Mice were sacrificed and tumors
were harvested after 6 weeks post orthotopic tumor implantation. Measurements of
tumor volumes were collected using manual calipers. Tumor volumes for mice injected
with PANC-1 (n=-8) or three PANC-1 Lfng KO clones (n-8 for each group) were plotted
as mean + SEM. Deletion of Lfng catalytic active site resulted in reduction of tumor
volumes in two of three PANC-1 Lfng KO clones. Data is represented as mean + SEM. *,
p<0.05, n=8.
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Figure 42: Deletion of Lfng Catalytic Active Site Via CRISPR/Cas9 Inhibits In Vivo
Tumorigenicity of HGC-25 Human Pancreatic Cancer Cell Lines.
3 X 105 cells were implanted orthotopically into the pancreas of nude mice. Tumor
volume was measured using Visual Sonics Vevo 2100 Imaging. Image acquisitions were
performed using the enhanced abdominal measurement package in the B-mode and 3-D
mode settings. Mice were imaged weekly starting at 2 weeks post orthotopic tumor
implantation to 5 weeks using ultrasound to monitor development of the orthotopic
pancreatic cancer xenografts. (A) Representative tumor volume ultrasound images from
HGC-25 (left) and HGC-25 Lfng KO Clone 28 (right) at week 5 post tumor implantation.
(B) Quantification of tumor volumes generated from HGC-25 PC cells and corresponding
Lfng KO cells starting from two weeks to 5 weeks. Data is represented as mean + SEM.
*, p<0.05, n=8.
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Figure 43: Exogenous Expression of Lfng cDNA in HGC25 Lfng KO Cells Rescues
In Vivo Tumorigenicity.
3 X 105 cells were implanted orthotopically into the pancreas of nude mice. Tumor
volume was measured using Visual Sonics Vevo 2100 Imaging. Image acquisitions were
performed using the enhanced abdominal measurement package in the B-mode and 3-D
mode settings. Mice were imaged weekly starting at 2 weeks post orthotopic tumor
implantation to 5 weeks using ultrasound to monitor development of the orthotopic
pancreatic cancer xenografts. Comparison of tumor volumes generated from HGC-25
PC cells, HGC-25 Lfng KO clone 42 and HGC-25 Lfng KO clone 42 transduced with
Lfng cDNA between 2 weeks to 5 weeks post tumor implantation. Data is represented as
mean + SEM. *, p<0.05, n=8.
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Figure 44: CRISPR/Cas9-Mediated Deletion of Lfng Catalytic Active Site Impacts
the Metastatic Spread of Human Pancreatic Cancer Cell Lines.
Spleen, liver, diaphragm, lung were collected from tumor bearing mice described in
Figure 40 and Figure 41. Presence of metastasis in individual mice was assessed
histologically in (A) MIA PaCa-2 and its corresponding Lfng KO clones (B) PANC-1 and
its corresponding Lfng KO clones. Deletion of Lfng in MIA PaCa-2 and PANC-1 human
pancreatic cancer cells resulted in decreased metastases in xenografts.
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Figure 45: CRISPR/Cas9-Mediated Deletion of Lfng Impacts Transcriptional Profile
of Human Pancreatic Cancer Cell Lines
(A-B) Venn diagram representing significantly (A) upregulated and (B) downregulated
genes in MIA PaCa-2, Panc-1 PC cell lines and their corresponding Lfng KO cell lines.
(C-D) Heat map representing downregulated and upregulated genes in MIA PaCa-2,
PANC-1 cell lines and their corresponding Lfng KO clones. Each row represents a
different gene and each column represents a different comparison. The scale on the
right represents the log2fold change color gradient.
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Figure 46: Comparison of OPHN1 Expression in Parental Pancreatic Cancer Cells
and Their Corresponding Lfng KO.
Gene expression of OPHN1 was determined in (A) MIA PaCa-2 (B) PANC-1 cell lines
and their corresponding Lfng KO cells. Quantitative real-time PCR was performed
described using SYBR green reagent as described in Materials and Methods. The
expression level of OPHN1 mRNA is normalized to 18SRNA and presented as relative
expression compared to the corresponding parental cell line. All reactions were carried
out using 50ng of cDNA per 25µl qPCR reaction. One-way ANOVA and Dunnet’s
multiple comparison post-test was performed to determine significance. *** p<0.001
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Figure 47: Comparison of Pim1 Expression in Parental Pancreatic Cancer Cells
and Their Corresponding Lfng KO.
Quantitative real-time PCR comparing the relative expression of PIM1 gene in (A) MIA
PaCa-2 (B) PANC-1 cell lines and their corresponding Lfng KO cells. Quantitative realtime PCR was performed described using SYBR green reagent as described in
Materials and Methods. The expression level of PIM1 mRNA is normalized to 18SRNA
and presented as relative expression compared to the corresponding parental cell line.
All reactions were carried out using 50ng of cDNA per 25µl qPCR reaction. One-way
ANOVA and Dunnet’s multiple comparison post-test was performed to determine
significance. *** p<0.001
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Figure 48: Comparison of TYMS Expression in Parental Pancreatic Cancer Cells
and their Corresponding Lfng KO.
Quantitative real-time PCR comparing the relative expression of TYMS gene in (A) MIA
PaCa-2 (B) PANC-1 cell lines and their corresponding Lfng KO cells. The expression
level of TYMS mRNA is normalized to 18SRNA and presented as relative expression
compared to the corresponding parental cell line. All reactions were carried out using
50ng of cDNA per 25µl qPCR reaction. One-way ANOVA and Dunnet’s multiple
comparison post-test was performed to determine significance. *** p<0.001
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Figure 49: Comparison of BCL2L11 Expression in Parental Pancreatic Cancer
Cells and Their Corresponding Lfng KO.
Quantitative real-time PCR comparing the relative expression of BCL2L11gene in (A)
MIA PaCa-2 (B) PANC-1 cell lines and their corresponding Lfng KO cells. The
expression level of BCL2L11 mRNA is normalized to 18SRNA and presented as relative
expression compared to the corresponding parental cell line. All reactions were carried
out using 50ng of cDNA per 25µl qPCR reaction. One-way ANOVA and Dunnet’s
multiple comparison post-test was performed to determine significance. *** p<0.001
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Figure 50: Loss of Lfng catalytic active site is Associated with Decreased Cav1
Expression in Human Pancreatic Cancer Cells
Deletion of Lfng catalytic active site in MIA PaCa-2 and PANC-1 human pancreatic
cancer cell lines was associated with a decrease in Cav1 expression as verified using
quantitative real-time PCR (A-B) For quantitative real-time PCR, the Cav1 gene
expression was normalized to expression of 18sRNA gene expression that was run
separately for each sample. All reactions were carried out using 50ng of cDNA per 25µl
qPCR reaction. In the graph *** represent p<0.0001 was obtained by Students-t test. (CD) Western blot analysis was performed to compare the Cav1 protein expression in
whole cell lysates obtained from parental pancreatic cancer cells and their
corresponding Lfng KO clones. Each well was loaded with 35µg protein lysate. (C)
Western blot analysis was performed using to compare the expression of Cav1 in MIA
PaCa-2 cells and their corresponding Lfng KO cells. (D) Western blot analysis was
performed to compare the expression of Cav1 in PANC-1 cells and their corresponding
Lfng KO cells. β-actin was used to evaluate protein loading in gels.
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Figure 51: NICD Localization to FoxM1 Promoter Region using ChIP.
A. Genomic structure of human FoxM1 gene showing intron-exon organization. Bars
represent the location of the ChIP primers used testing the Notch1 Intracellular Domain
(NICD) localization to FoxM1 promoter regions.
(B-C) Cross-lined chromatin was prepared from PANC-1, MIA PaCa-2 human pancreatic
cancer cell lines and their corresponding Lfng KO clones. The chromatin was
immunoprecipitated using NICD antibody or IgG control. Primers specific to FoxM1 gene
were used to assess the binding of NICD to FoxM1 promoter. Deletion of Lfng results in
decreased NICD localization at FoxM1 promoters in (B-C) PANC-1 and (D) MIA PaCa-2
cells
(E and F) Decreased promoter localization of NICD at FoxM1 promoter region correlates
with reduced FoxM1 mRNA expression in Lfng KO (E) MIA PaCa2 and (F) Lfng KO
PANC-1 cell lines as compared to their parental controls. Quantitative real-time PCR
gene expression is normalized to GAPDH gene expression run separately for each
sample. Data is represented as mean + SEM. *, p<0.05. **, p<0.01, and ***, p<0.001.
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Figure 52: CRISPR/Cas9-Mediated Deletion of Lfng Catalytic Active Site Impacts
Metabolic Profile of Human Pancreatic Cancer Cell Lines.
(A-B) Heat map showing unsupervised hierarchical clustering analysis. The heat maps
show the relative analysis performed using the polar metabolite data obtained from
parental pancreatic cancer cell lines and their corresponding Lfng KO clones. Each
column represents a biological replicate within the sample while each row represents
individual metabolite. The color scale ranging from green to black to red indicates the
relative change in expression of the metabolite. The dendrograms on top of the figure
represent that the parental pancreatic cancer cell lines have different metabolic profile
than their corresponding Lfng KO clones.
(C-D) Partial least square-discriminant analysis (PLS-DA) plots representing separation
of (C) MIA PaCa-2, (D) PANC-1 and their corresponding Lfng KO clones. The axes of
the PLS-DA plot indicate Principle Component -1 (PC-1) and -3 (PC-3), which indicate
variance among the groups. Parental pancreatic cancer cells (red) and their Lfng KO
clones (blue or green) based on their polar metabolite contents. Each colored circle
indicates one replicate of the group. Component 1 indicates the degree of variation
between the parental pancreatic cancer cells and Lfng KO groups based on their polar
metabolite content, and component 2 indicates the differences within the groups. Red
dots represent the metabolic profile changes in human PC cell lines upon deletion of
Lfng.
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Figure 53: Snapshot of Significantly Impacted Metabolic Pathways Upon
CRISPR/Cas9-Mediated Deletion of Lfng Catalytic Active Site in Human Pancreatic
Cancer Cell Lines. Pathways significantly altered in (A) MIA PaCa-2 (B) PANC-1 upon
CRISPR/Cas9 mediated deletion of Lfng catalytic active site. The greater the number of
metabolites impacted in the input data and the MetaboAnalyst Pathway databases, the
bigger the size of the circle. The brighter the color gradient used to fill the circles, the
more statistically significant the values. Statistical significance decreased from dark red
circles, which are highly significant to light yellow, which are less significant. Thus, the
pathways greatly impacted and highly significant are identified with high p-values and
bigger brighter circles.
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Figure 54: CRISPR-Mediated Deletion of Lfng Impacts Nucleotide Biosynthesis in
MIA PaCa-2 Pancreatic Cancer Cells.
Comparison of nucleotide metabolic profile of MIA PaCa-2 and its corresponding Lfng
KO clones. The bar graphs represent the fold change in nucleotide mono-, di-, and triphosphate levels in MIA PaCa-2 Lfng KO clones relative to MIA PaCa-2 parental cells.
Data is represented as mean + SEM. *, p<0.05. **, p<0.01, and ***, p<0.001, n=3.
Statistical significance between MIA PaCa-2 and corresponding Lfng KO clones was
obtained through one-way ANOVA.
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Figure 55: CRISPR-Mediated Deletion of Lfng Impacts Nucleotide Biosynthesis in
PANC-1 Pancreatic Cancer Cells.
Comparison of nucleotide metabolic profile of PANC-1 and its corresponding Lfng KO
clones. The bar graphs represent the fold change in nucleotide mono-, di-, and triphosphate levels in PANC-1 Lfng KO clones relative to PANC-1 parental cells. Data is
represented as mean + SEM. *, p<0.05. **, p<0.01, and ***, p<0.001, n=3. Statistical
significance between PANC-1 and corresponding Lfng KO clones was obtained through
one-way ANOVA.
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Figure 56: CRISPR-Mediated Deletion of Lfng Impacts Glycolytic Pathway
Metabolites
(A-B) Bar graphs represent the relative fold changes in polar metabolites levels of
glycolysis pathway in human pancreatic cancer cell lines (A) MIA PaCa-2 (B) PANC-1
upon CRISPR-mediated deletion of Lfng. The data is represented as mean + SEM. *,
p<0.05. **, p<0.01, and ***, p<0.001, n=3. Statistical significance between PANC-1 and
corresponding Lfng KO clones was obtained through one-way ANOVA.
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Figure 57: CRISPR-Mediated Deletion of Lfng Impacts Pentose Phosphate
Pathway Metabolites
(A-B) Bar graphs represent the relative fold changes in polar metabolites levels of
pentose phosphate pathway in human pancreatic cancer cell lines (A) MIA PaCa-2 (B)
PANC-1 upon CRISPR-mediated deletion of Lfng. The data is represented as mean +
SEM. *, p<0.05. **, p<0.01, and ***, p<0.001, n=3. Statistical significance between
PANC-1 and corresponding Lfng KO clones was obtained through one-way ANOVA.
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Figure 58: CRISPR-Mediated Deletion of Lfng Does Not Impact Tricarboxylic Acid
(TCA) Pathway Metabolites
(A-B) Bar graphs represent the relative fold changes in polar metabolites levels of TCA
pathway in human pancreatic cancer cell lines (A) PANC-1 (B) MIA PaCa-2 upon
CRISPR/Cas9-mediated deletion of Lfng. The data is represented as mean + SEM. n.s,
not significant, *, p<0.05. **, p<0.01, and ***, p<0.001, n=3. Statistical significance
between PANC-1 and corresponding Lfng KO clones was obtained through one-way
ANOVA.
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DISCUSSION and FUTURE DIRECTIONS

Immunohistochemical assessment of Lfng, a Notch-related glycosyltransferase,
in human PDAC specimens revealed elevated expression in human PDAC specimens.
While we show that Lfng expression and Notch receptor expression (substrate for the
enzyme) are elevated in PDAC, studies confirming the expression of glycans on specific
Notch receptors need to be performed in the future. Analysis of the changes in Notch
glycosylation in human pancreatic cancer specimens will provide insights into the
changes in Notch glycosylation during pancreatic cancer.
We show that deletion of Lfng impacts pancreatic cancer progression.
Interestingly, there were contrasting results in GEMM and human pancreatic cancer cell
lines models. Our findings suggest an oncojanus role of Lfng in pancreatic cancer. A
specific mouse model in which Lfng was deleted in the pancreas starting at day 8.5,
commensurate with introduction of mutated alleles of Kras and p53 enhanced tumor
formation and progression. In contrast normal adult human pancreas shows low levels of
expression of Notch and Lfng, and human tumors show dramatically higher levels of
expression of these proteins. Deletion of Lfng in established tumors cell lines inhibited
tumor growth properties. Previous studies have shown that genes can often have dual
roles; in particular, it can be necessary for tumor suppression and malignancy depending
on the context. We believe that one of the reasons for the observed differences could be
due to temporal effects of Lfng. The elucidation of spatial and temporal expression of
Lfng during different stages of normal pancreas development and PDAC progression will
help dissect the role of Lfng in PDAC. One way of addressing this question is to use of
tamoxifen-inducible Cre models of PDAC. This model would allow us to deletion Lfng
during different stages of pancreatic cancer progression.
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Cancer is often associated with reprogramming of metabolic and transcriptional
pathways (148). Reprogramming of transcriptional pathways enable the cancer cells to
enhance tumorigenic properties such as cellular proliferation and tumor invasiveness. In
order to sustain the tumorigenic processes, the cancer cells also reprogram their
metabolic processes. We have shown that deletion of Lfng in human pancreatic cancer
cell lines results in changes in global changes in transcriptional and metabolic profile of
human pancreatic cancer cell lines. Detailed analysis of polar metabolites revealed that
deletion of Lfng results decreased several metabolites involved in the nucleotide
biosynthesis. The decreased in vitro cellular proliferation observed upon deletion of Lfng
in human pancreatic cancer could be a result of decreased nucleotide biosynthesis.
Studies have illustrated that Notch signaling can impact cellular metabolism in normal
and cancer context (149–151). How does the alteration in Notch glycosylation drive
metabolic reprogramming in pancreatic cancer cells? While the mechanisms driving
through which Lfng mediates metabolic reprogramming have not been clearly elucidated
we believe that using CRISPR/Cas9 Lfng KO cells and exogenous Lfng expression
systems we may be able identify the molecular mechanisms.
Previous reports have shown that increased expression of Cav1 in cancer cells is
associated with increased progression (156,169,170), drug resistance (170,171) and
also involved in metabolic regulation (172). We show that deletion of Lfng in human
pancreatic cancer cell lines resulted in decreased transcription and protein expression of
Cav1 gene. To further assess the mechanism via which Lfng regulated Cav1 expression
in human pancreatic cancer cells, we performed a ChIP experiment using NICD
antibody. We showed that that deletion of Lfng decreased the localization of NICD to
three regions of FoxM1 gene. FoxM1 has been previously shown to be one of the
regulators of Cav1 expression in pancreatic cancer. Thus we show that deletion of Lfng
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altered localization of NICD to FoxM1 gene. It is possible that Lfng mediated
glycosylation of Notch receptors could regulate localization of NICD to different genes. It
is also possible that glycosylation status of Notch receptor alter the downstream binding
partners of NICD in the nucleus. Further mechanistic evaluation is necessary to evaluate
if extracellular glycosylation can actually mediate changes in NICD localization inside the
cell.
Alteration in metabolic pathways are often associated with response to drug
therapy (173–175). Would decreased synthesis of nucleotides drive in Lfng KO human
pancreatic cancer cell lines result in increased sensitivity of nucleotide analogs in these
cells? Increased metabolic processing of drugs is often associated with poor drug
response to chemotherapeutic reagents. We also observe decreased expression of
metabolic enzyme TYMS. Increased expression of TYMS is often associated with 5-FU
resistance (175). In the future, it would be prudent to evaluate the effect of Lfng deletion
on 5-FU and gemcitabine drug sensitivity.
We observe that while deletion of Lfng increased Hes1 transcription. Increased
Hes1 is often suggested as an increased Notch signaling activity. While the observed
increase in Hes1 transcription could result from increased Notch signaling activation,
other signaling pathways can also drive the transcription of Hes1 independent of the
Notch signaling pathway (176,177). Deletion of Lfng may result in increased activation of
other pathways that drive Hes1. We propose to evaluate the whether increased
transcription is driven by Notch signaling pathway in Lfng KO human pancreatic cancer
cell lines using gamma secretase Notch inhibitors.
Pancreatic cancer patients are often present with extensive metastasis,
perineural invasion (178), and invasion into lymph nodes (179). Notch mediated cell-cell
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interactions are a crucial to many biological processes: essential for developmental
events, tissue homeostasis and cancer progression (180,181). Notch signaling has
been shown to mediate intercellular communication between tumor cells and other cell
types in the tumor microenvironment. Such intercellular communication helps the tumor
cells reconfigure its environments making them conducive for growth, immune evasion,
and metastasis. Depending on the cellular environments the tumor cell encounter, the
cancer cells may fine-tune the cell surface glycosylation of Notch in order for it to interact
with different cell types.
Several Notch signaling proteins show variable capacities in the tumor cells as
well as non-tumor cells. Given the broad extent of Notch signaling protein expression in
the pancreatic cancer microenvironment (49), it is possible that Notch signaling mediates
intercellular communication between the tumor cells and other cells present in the tumor
microenvironment. The Notch signaling has been shown to mediate homotypic and
heterotypic interactions between various tumor cells and other cell types present in the
tumor microenvironment.
Here we characterized the impact of Lfng deletion on the properties of pancreatic
cancer cell lines. We have also shown how deletion of Lfng impacts the transcriptional
and metabolic profile of pancreatic cancer cell lines. What remains to be explored is the
impact of Lfng expression by tumor cells in modulating intercellular communication
between tumor cells and other cell types in the tumor microenvironment. It is possible
that aberrant expression of Lfng in tumor cells modulates Notch signaling to mediate
these interactions. Recently, deep tissue imaging had made it possible to interrogate the
changes in neuronal, blood vessels and lymphatic networks.
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To understand the impact of Lfng on the organization of tumor microenvironment
we propose to perform CLARITY (Clear Lipid-exchanged Acrylamide-hybridized Rigid
Imaging Tissue hYdrogel) which is a technique involving tissue clearing to assess the
structural and molecular changes in tissues. We have previously conducted preliminary
studies to assess the feasibility of this technique using human pancreas. As proof of
principle we harvested mouse pancreas from a healthy mouse and cleared it using
passive clearing technique. Using this technique we were able to acquire images of
different structures of the normal pancreas such as the nerves, lymphatic vessels, and
blood vessels (Figure 59). We are confident that in the future we would be able to use
this technique to address the effect of the aberrant expression of Lfng in pancreatic
cancer on the other compartments of the pancreatic cancer tumor microenvironment.
Using parental, Lfng KO or Lfng overexpressing pancreatic cancer cell lines co-cultured
with different cells types present in the tumor microenvironment can also be designed to
study the impact on heterotypic Notch signaling between different compartments.
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Figure 59: Nerve, Lymphatic and Blood Vessel Network of Mouse Pancreas
Revealed by CLARITY and 2-Photon Microscopy.
Mice were perfused with CLARITY hydrogel monomer solution as previously described
to achieve optimal tissue perfusion as previously (182). The pancreases were harvested
and further clarified as per CLARITY protocol (182). The pancreases were embedded in
3% agarose solution and cut into approximately 300 um sections using a vibratome.
The sections were incubated with antibodies raised against markers specifically
recognizing nerves (b-III-tubulin), lymphatic vessels (Lyve-1) and blood vessels (CD-31).
The sections were imaged using a 2-photon confocal imaging after incubation with
fluorophore-labeled secondary antibodies. (A-B) 3D projection of nerves (green color),
blood vessels (purple) and lymphatic vessels (red color) in the normal mouse pancreas.
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